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ABSTRACT
Alzheimer´s disease (AD) is accompanied by neural degeneration with loss off dendrites and 
synapses. The ganglioside GM1 has been shown, but not in AD, to have positive influence on 
the nerve cells and stimulate growth of dendrites and synapse formation. Mental stimulation 
has also been shown to have similar and therapeutic positive effects. Theoretically those two 
treatments could together give an answer of it is possible to reverse impairments in AD. 
In two studies GM 1 was given intrathecally, to pass the blood brain barrier, in combination 
with a training treatment. In the first one year study five patients with AD were activated by 
daily activities carried out at home by the spouses. They were supported with the activation 
but this diminished with time. The study indicated that the patients increased their willing to 
and of active performances. The effect of GM1 was very dos dependent and showed increased 
levels of transmitters. A mix of some improvement and decreased values was shown in the 
neuropsychological assessments. The study was summarised in Paper I. 
In the next one year study the GM1 treatment was combined with a newly developed 
programme with Simulation, Activation and Training carried out by professional in a 
homelike setting (paper II). The patients were highly engaged in the SATprogramme. The 
Paper III described the SATprogramme, the systematic training, the various form of direct and 
indirect stimulation, and of practical performance of cognitive, social and physical activities 
of daily life. The results demonstrated after one year the patients had shown ability to an 
active participating, specified in the complex activity performance, ability to use of remaining 
abilities in compensatory strategy, and competence to learn and use a new tool, a personal 
computer system. The examinations showed scores of preserved and improvement ability. 
Paper IV evaluates monthly reaction from the spouses of the patients, which provided 
information of the daily life at home as related to AD. These notes were voluntary comments 
given during one year. Four themes emerged of which the partner’s social and activity level 
was evident. The results suggested educational interventions to be tailored to spouses with use 
of different caregiving perspective due to the visually complex symptoms and of recognizing 
healthy emotions which may prevent problems of incidents. 
Paper V assessed linguistic development during the one year treatment in the SAT 
programme. The language sessions was interlaced in the cognitive and social training in 
which a computer further stimulated the patients to use their preserved language ability. The 
assessment showed that a group pattern occurred of language comprehension, the cornerstone 
of everyday life. The scores were maximum on reading comprehension and reading aloud 
during the whole assessment in spite of their dyscalculia or poor arithmetic ability. 
These studies suggest that in order to improve cognitive functions in pharmacological 
interventions to further enhance the treatment effect, by offering a rich homelike setting, and 
practical activities of normal daily life, adapted to individual capacity. The studies imply the 
importance of adequate intervention of use of various ways to stimulation of remaining 
abilities to practical performance in active participating of daily life. The studies stress the 
need in order to reach optimal treatment, to use a combination of a pharmacological agent and 
the influence of adopted environmental stimulation. This is probably necessary to influence 
the neural degeneration of patients with early onset mild to moderate AD. 
Keywords: Alzheimer disease, GM 1, ganglioside, intracerebroventricular, transmitter 
substances, stimulation, activation, training programme, spouses experiences, linguistic, 
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evaluations of neuropsychological examinations indicate individual more preserved 
and slight improvement than decreased values. The increased levels of transmitters may 
suggest GM1 exerting a neurotrophic effect. 
SVENSK SAMMANFATTNING 
Vid Alzheimers sjukdom (AD) sker en tilltagande nedsättning av kognitiva funktioner vilket orsakas 
av degenerativa förändringar i hjärnan med förlust av nervcellsutskott (dendriter) och kontaktpunkter 
(synapser). Gangliosid GM1har vid behandling av hjärnskador visats stimulera utväxt av dendriter och 
bildning av nya synapser. Mental stimulering har också visat sig att ha liknande positiva effekter. 
Teoretiskt skulle dessa två behandlingar tillsammans ge ett svar om det är möjligt förbättra funktion 
vid AD.   
I två studier har gangliosid GM1 givits direkt in i hjärnans hålrum, detta för att passera blod- hjärn-
barriären. Behandlingen har kombinerats med en mental stimulering. I den första ettåriga studien var 
fem patienter med AD aktiverade med dagliga uppgifter i bostaden av sin make/maka. Det visade sig 
att aktiveringen minskade gradvis under behandlingsåret. Studien indikerade att patienterna ökade sin 
villighet till aktivitet och också att utförande uppgifter.  Analyser av ryggvätska tydde på ökade nivåer 
av transmittorsubstanser. De neuropsykologiska mätningarna visade inga säkra tendenser. Studien är 
sammanfattad i Arbete I. 
I den följande studien, Arbete II, kombinerades GM1 behandlingen med ett nyutvecklat program med 
Stimulering, Aktivering och Träning (SAT), som leddes av utbildad personal i en hemlik miljö. 
Patienterna var i hög grad engagerade i programmet. Utvärderingarna av neuropsykologiska mätningar 
tydde på svag förbättring eller oförändrar funktion. Ryggvätskeanalyser antydde positive effekter.  
I Arbete III beskrivs den systematiska träningen, SATprogrammet, de olika formerna av direkt och 
indirekt stimulering samt även av praktisk utförande av kognitiv, social och fysiska dagliga aktiviteter. 
Resultaten pekar på att efter behandlingsåret så hade patienterna visat förmåga till ett aktivt 
deltagande, utförande av komplexa aktiviteter, förmåga att använda kvarvarande förmågor som 
kompensatoriska strategier och kompetens att lära sig och att använda en dator, vilket de inte gjort 
tidigare. Utvärderingar visade på bibehållen eller förbättrad förmåga.  
I Arbete IV utvärderas månadsvisa anteckningar, gjorda av patienternas make/make under 
behandlingsåret. De gav kunskap om det dagliga livet i hemmet, och hur det påverkades av 
sjukdomen. Fyra teman framkom i en kvalitativ analys. Resultaten antyder att utbildning skall vara 
anpassad till äkta make/makars olika perspektiv, bl. a gällande vissa komplexa symptom. Det är också 
viktigt att lära sig förstå friska känsloutbrott för att undvika feltolkning. 
 I Arbete V skattas den språkliga utvecklingen under behandlingsåret. De språkliga övningarna var 
sammankopplade med den kognitiva och sociala träningen och i vilken en dator ytterligare stimulerade 
patienterna att använda sina språkförmågor. Patienterna hade maximumpoäng i läsförståelse och 
högläsning genom hela skattningen trots nedsatt räkneförmåga.  
Dessa studier lyfter fram att en rik hemlik omgivning med praktiska aktiviteter som användas i dagligt 
liv och anpassad till individidens kapacitet kan användas för att stimulera kognitiva funktioner. Detta 
kan också vara ett komplement till läkemedelsbehandling av AD och tillsammans möjliggöra en större 
förbättring, framförallt vid behandling med nervcellsstimulerande läkemedel. Studierna lyfter fram 
vikten av att utnyttja bevarade funktioner för att kompensera för förlorade förmågor. Trots att 
patienterna hade en demenssjukdom, mild till måttlig AD, fanns möjlighet till nyinlärning.  
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1   INTRODUCTION 
Dementia has been classified as a major worldwide health challenge in elderly persons by the 
World Health Organisation [1] due to the progressive aging of the population, the creating of 
a dependence on other people, and a major cause of institutionalization. The most common 
form of dementia is Alzheimer’s disease, representing about 60% of all dementia cases, and 
the second form is vascular dementia. When incidence data carried out from eight population-
based studies of dementia and subtypes in seven European countries (including Sweden) was 
compared and pooled, 60 to 70% of all demented cases were diagnosed with AD [2]. 
In modern society dementia is widespread and the worldwide social cost of dementia based on 
prevalence estimates, a population of 34.4 million demented persons, was estimated to $422 
billion US dollars ($) in 2009. This includes $142 billion for informal care [3]. In Sweden the 
direct costs in year 2009 are rough estimated to 2069.8 (millions US$) for 145535 persons 
and including informal care 1.6 h/d or 3.7 h/d the total cost was 2899.2 (millions US$) 
respective 3987.7 (millions US$) [3].  
The progressive loss of nerve processes is the neurobiological basis of the progressive 
deterioration in AD, characterized by ongoing neurodegeneration [4]. As there is yet no cure 
for AD, the goals for treatment is temporary retardation of the progress of the disease, which 
is reflected in the general pattern of decline and in the continuous deterioration of cognitive 
and social functioning.  
Synapse loss as primary event in early-onset AD has been suggested [5] and is together with 
nerve cell loss the probable basis of the cognitive reduction. Recent development in 
neurotrophic factor research has opened for new treatment strategies in neurodegenerative 
diseases. Factors with possible effect/influence on the density of synapses could have a 
positive effect on the disease. Gangliosides, especially ganglioside GM1, have been shown to 
have neuritogenic and neurotrophic activity.  GM1 is in CNS concentrated in the pre-and 
postsynaptic membranes of the synaptic terminals, in the synaptic junction [6].  Treatment 
with ganglioside GM1 has in clinical trials shown to made beneficial effects on brain damage 
as well as in stroke.  
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The brain’s ability to reorganize itself by forming new neural connections throughout life is 
called neuroplasticity. Mesulam [7] described neuronal plasticity as a life-long process that 
mediates the structural and functional reaction of dendrites, axons, and synapses to 
experience, attrition, and injury. The manifestations of neuroplasticity in the adult CNS 
include alterations of dendritic ramifications, synaptic remodeling, axonal sprouting, neurite 
extension, synaptogenesis. GM1 might therefore be able to exert a positive effect on the loss 
of synapses in AD, which is supposed to reflect the reduced cognitive function in the disorder. 
In a previous study it was evident that subcutaneous or intra muscular injection of GM1 
ganglioside for three months had no clinical effects on cognitive and emotional disturbance in 
AD [8]. The study also showed the GM1 cannot pass the blood-brain barrier. Accordingly, it 
was necessary to develop: a technique for infusion of GM1 into the brain for treatment of 
neurodegenerative disorders in the brain.  
Early research on how brain aging and AD are influenced by activating stimuli, which affect 
neuronal functioning, suggest that environmental stimuli, transmitters and trophic factors can 
all influence the brain. We have combined two of these factors in a hope to obtain 
functionally relevant effects. Within the hypothesis to “use or lose it”, was said that activation 
of neurones may promote functional cell survival or even prevent cell death [9]. There was 
also in the research, support of the hypothesis that at least a certain amount of neuronal 
survival and plasticity in AD remains, and is “use-dependent”. Active interaction of the AD 
subject with the environment was required for plasticity to take place. These points to 
plasticity in the brain, suggesting that mental activation can modulate symptoms. Another 
form of plasticity related to memory was found in the hippocampus in which the plasticity 
occurs at synapse level. Further, it was suggested that a certain level of neuronal plasticity 
persists in AD [10].  
The basic thoughts of this project were thus: if treatment with ganglioside GM1 could have 
positive effects, a stimulation - activation- training with cognitive, social and physical 
activities was combined as an additive therapeutic treatment. The programme (intervention) 
was made to use and supply retained functions of the patient to compensate for impairment 
[11, 12, 13, 14]. If any clinical improvements are observed of the therapeutic use of such a 
training program and of ganglioside GM1 administration, this would show that it was possible 
to improve brain function in AD.  
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Therefore the first treated patients and their respective caregiver are important participants to 
provide a well-carried out and well-followed up of the conducted extensive combined 
treatment. Especially important is the developed programme: to describe the content, the 
individual design, the execution in the real world, and information to and from the close 
caregivers of the patients.  
The new technique for administration of GM1 and the addition of training made it necessary 
to get knowledge of: how the practicability of ganglioside GM1 administration was feasible; 
how the practicability of a training programme developed to enhance the remaining capacity 
of the patient to be used in active participating was feasible; how ganglioside GM1 and the 
performance of this training programme exert influence on the treatments given; in that 
purpose there were use of extensive and continuing of examinations of standardized 
assessment tools together with empirical data based on all assessment tests, form, imaging 
techniques and interviews. Evaluation, qualitative and quantitative methods provide 
knowledge about how well the collected data correspondence to the dimensions it was meant 
to deliver. A well done description of the interventions can then be used as knowledge before 
new start of interventions; it is the way we teach each other, to provide what is happening 
during the ongoing research.   
This thesis, intends to provide new knowledge from nursing care aspects; about providing 
optimal therapeutic treatments in early onset AD patients, about dementia care nursing 
treatments intended to induce brain stimulation; about containing of utilizing compensatory 
approaches in a training programme with regards to brain damage and home living conditions; 
about influences, treatments, managements, supervisions, and possible adverse events of these 
new treatments.  
This thesis intends to provide knowledge about: the capacity of each patient to actively 
participate in all activities within the programme; about the patients’ experiences of the 
treatments given; and of spouses’ depicted opinions of the treatment based on the everyday 
life at home.  
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1.1 The complex of investigations in Alzheimer’s disease 
The disease is named after Alois Alzheimer. He published a case report in 1907 on a woman 
with impairments supplemented with post mortem neuropathological findings of 
neurofibrillary tangles and senile plaques that have subsequently become the hallmarks of AD 
[15]. Such a definition means that the diagnosis is only definite at autopsy, but a probable 
diagnose can be made on the basis of a thorough clinical examinations weighed together with 
information gathered from supplementary investigations [16].  
A well specified clinical diagnose is necessary in both clinic and research , and a correct 
diagnosis would also lead to a better understanding of the needs of the patients and thereby 
better care and quality of life. A correct diagnose is therefore crucial in pharmacological 
treatment. 
Pathology. There is a consensus that the main microscopic findings in the AD brain are 
neurofibrillary tangles (NFT), senile plaques (SP) and degeneration of neurons and synapses 
[15, 17, 18]. NFT are one of the hallmarks of AD and composed of abnormal fibrillary 
material which has accumulated in the cytoplasm of neurons [19]. SP consists also of an 
acellular core material formed by beta-amyloid and surrounded by a variety of neural and 
glial processes. The term neuritic plaques [20, 21, 22] is used synonymously.  β-amyloid is the 
key protein component deposited in senile plaques in the brain in AD.  
Diagnostics. Clinical diagnosis can be based on different criteria-based diagnostic systems. 
The most commonly used are: the National Institute of Neurological and Communicative 
Disorders and Stroke – Alzheimer’s disease and Related Disorders Association (NINCDS-
ADRDA) [16]  and or the revised 1984 criteria  with the note that: “... all patients who met 
criteria for “probable AD” by the 1984 NINCDS-ADRDA would meet the current criteria for 
probable AD dementia mentioned in the present article” [23]; the Diagnostic and Statistical 
Manual of Mental Disorders, 3rd edition (DSM-III-R) [24], and or 4th edition DSM-IV [25]; 
and the International Classification of Disease, (ICD 10th revision) [26]. 
When this study was carried out, the best diagnosis method was NINCDS-ADRDA [16]:
Definite AD:  requires in this criteria histopathological evidence of AD, which is regarded as 
the gold standard, plus clinical evidence for probable AD.  
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[15, 17, 18]. NFT are one of the hallmarks of AD and composed of abnormal fibrillary
material which has accumulated in the cytoplasm of neurons [19]. SP consists also of an 
acellular core material formed by beta-amyloid and surrounded by a variety of neural and 
glial processes. The term neuritic plaques [20, 21, 22] is used synonymously. β-amyloid is the
key protein component deposited in senile plaques in the brain in AD. 
Diagnostics. Clinical diagnosis can be based on different criteria-based diagnostic systems. 
The most commonly used are: the National Institute of Neurological and Communicative
Disorders and Stroke – Alzheimer’s disease and Related Disorders Association (NINCDS-
ADRDA) [16] and or the revised 1984 criteria  with the note that: “... all patients who met 
criteria for “probable AD” by the 1984 NINCDS-ADRDA would meet the current criteria for
probable AD dementia mentioned in the present article” [23]; the Diagnostic and Statistical 
Manual of Mental Disorders, 3rd edition (DSM-III-R) [24], and or 4th edition DSM-IV [25]; 
and the International Classification of Disease, (ICD 10th revision) [26].
When this study was carried out, the best diagnosis method was NINCDS-ADRDA [16]:
Definite AD:  requires in this criteria histopathological evidence of AD, which is regarded as 
the gold standard, plus clinical evidence for probable AD.
5 
Probable AD: requires deficits in two or more areas of condition; progressive worsening of 
memory and other cognitive functions, no disturbances of consciousness, onset between the 
ages 40-90 and absence of systemic brain disorders that could explain the memory or 
cognitive decline. The diagnosis is supported by progressive deterioration of specific 
functions such as aphasia, apraxia, agnosia and impaired ADL.  
Possible AD: is diagnosed when the patient has dementia with a clinical course that resembles 
AD, but also has a second brain disorder or systemic illness that is sufficient to produce 
dementia but is not considered to be the cause of the dementia. The patient has a progressive 
deficit in the absence of any other cause.  
New strategies for the diagnoses of Alzheimer´s disease have been proposed after this study 
was made [27]. These criteria include also analyses of structural MRI, molecular 
neuroimaging with PET, and cerebrospinal fluid analyses and are centred on a clinical core of 
early and significant episodic memory impairment. 
Clinical diagnosis of subgroups 
The German psychiatrist and neuropathologist Alois Alzheimer was the first to describe this 
disease in 1907, a heterogeneous dementia disease [15]. Several studies have shown 
differences between early-onset AD, type I (<65 years of age) and late-onset of AD, type II. 
Criteria of early onset AD and late onset AD have been presented. 
Patients in early-onset AD have a greater frequency and intensity of parietal symptoms, [28, 
29] and normal blood-barrier function [28], more aphasia, agnosia and apraxia [30].  Patients
with AD type II, mainly in late onset, have mild tendency to develop delirium, but mild if any 
parietal-lobe symptoms [31]. 
According to fundamental biochemical differences between the two major forms of AD, 
results in a study suggested a pronounced loss of nerve endings in early-onset AD [32]. 
Instead, the white matter changes are more frequent and more severe in patients with late 
onset [33].  
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Clinical diagnosis of early onset AD 
To meet the demands of matching the development of e.g. new techniques for biochemical 
investigations on the etiology and pathogenesis and new drugs for AD, criteria for the clinical 
diagnosis of “pure” AD has been presented. Research criteria for the clinical diagnosis of 
“pure” (classic) AD are documented by Wallin and his colleagues [32] are as follows. The 
characteristic symptomatology of “pure” AD is instrumental deficits. These deficits comprise 
visual agnosia, sensory aphasia, apraxia (in “pure” AD, the onset is insidious and the 
progression is even).  
In mildly demented AD patients the symptoms are often vague and diffuse, usually with 
memory as the most obvious finding. In moderately demented AD patients, a clear brain-
regional symptom pattern has usually developed such as predominance of instrumental 
deficits.  In severely demented patients the instrumental symptomatology may be obscured by 
the appearance of personality deficits and the global severity of dementia. These research 
criteria are used in this thesis. 
Symptomatology in Alzheimer’s disease 
The clinical picture and course of AD is assumed to reflect the biologic changes induced by 
the underlying disease. The aspect of the clinical course of AD is multidimensional. There are 
many scales for stages of the symptomatology, such as 7 STAGES in the GDS scale (Global 
Deterioration Scale [35] but in this thesis the three-stage model proposed by Sjögren and 
associates [30] has been used. 
STAGE 1. Manifest mnestic disturbances is the most prominent and incipient symptoms of 
dementia and observation of predominant aspontaneity and reduced initiative. The symptoms 
are often vague and diffuse and develop insidiously such as functions of speech, and 
disorientation in space. Disturbance in gait in earlier stages was localized in the forebrain.  
STAGE 2. The cardinal cortical disturbances dominate the symptoms, which are referred to as 
parietal symptoms as of dysphasia, dyspraxia, dysgnosia, and visuospatial disturbance, 
together with a progressive worsening of memory. There is a pronounced deterioration of 
speech faculty. Aspontaneity is predominant relatively common, occurrence of rigidity and 
high degree of increase of muscle-tonus occurs. Disturbance in gait and movements for 
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normal gait is observed in earlier stages. Initiative to walk is reduced. The gait disturbance in 
combination with changes in muscle-tonus is pronounced and characteristic.  
STAGE 3. The mental functions are severely impaired as the parietal symptoms become more 
and more concealed. There is preservation disturbances and the disturbance in gait at an early 
stage shown in the terminal stage a type “marche a petits pas” with a localization in the basal 
ganglia. Pronounced hypokinesis, the features are stiff, expressionless and mask-like. The 
well-known picture of a vegetative status are shown and also a picture of complete dementia 
with a rapid physical decline.  
Another often used clinical definition of mild, moderate and severe dementia is lined out in by 
the American Psychiatric Association [24] in the Diagnostic and Statistical manual of Mental 
Disorders: 
Mild dementia. Although work or social activities are significantly impaired, the capacity for 
independent living remains, with adequate hygiene and relatively intact judgment. 
Moderate dementia. Independent living is hazardous, and some degree of supervision is 
necessary. 
Severe dementia. Activities of daily living are so impaired that continual supervision is 
required, e.g., unable to maintain minimal personal hygiene; largely incoherent or mute. 
1 .2  Clinical investigations used in the studies   
Neurologic and neuropsychiatric identification of regional brain 
syndromes in dementia was outlined by stepwise comparative status analysis of regional brain 
syndromes (STEP) [36].   
This tool is a clinical method to assess emotional and motivational functions, the capacity for 
mental flexibility, instrumental functions, mental speed, basic neurological functions and 
general cognitive functions. When these functions are disturbed, STEP is then a clinical 
method to assess these deficits and their interactions recognizes the predominant 
symptomatology.  
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The outcome of the analysis of STEP is specific patterns of neuropsychiatric deficits.  This 
status examination relies on the examiner’s observations and a structured interview with the 
patient and the relative. The STEP status variables are: Primary variables (n = 35), Compound 
variables (n = 8), Complex variables (n = 7). The protocol is recording of scores (five score 
variables: 9, 0, 1, 2, 3) of the Primary Variables (n=35), the Compound Variables (n=8) and 
the Complex Variables (n=7).   
Neuropsychological assessment. Common used tests are of attention, 
language, memory, visuospatial skills, executive function, intelligence, and motor speed. 
These assess the major domains of neuropsychological functions as considered in Report of 
the Therapeutics and Technology Assessment Subcommittee of the American Academy of 
Neurology [37]. However, not all tests are used with each patient. Tests used in this thesis are 
referred to authors such as Fuld [38], Wechsler [39], Lezak [40], Rosen and associates [41].  
The Mini Mental state Examination (MMSE) was used as a screening instrument of several 
cognitive functions such as orientation, attention, recall, constructional ability and the use of 
language. Scores range between 0 (complete failure) and 30 (representing full marks), where 
score 0-23 indicates a state of dementia [42].   
Linguistic assessment. Norwegian Basic Aphasia Assessment “Norsk Grunntest 
for Afasi “ (NGA) was used for linguistic assessments. It is a Norwegian standardized test, 
based on patients with aphasia, for measuring degree and type of aphasic impairment. A 
detailed description of NGA, including its rationale, reliability, validity and origins is given 
by Reinvang under the heading Norwegian Basic Aphasia Assessment [43]. The standard test 
measures fluency, comprehension, repetition, naming, reading and writing, which are the 
complexity of linguistic problems common in patients diagnosed with AD. There is no such 
test or scale available based on or for patients with AD. The NGA is commonly used and 
carried out by speech language pathologist, educated in NGA assessment.  
Psychiatric physic assessment. The Body Awareness Scale (BAS) was used 
for psychiatric physic assessments. It is constructed by Roxendal and also tested in her thesis 
in treatment and evaluation in psychiatric physiotherapy [44]. The general purpose is to give 
the physiotherapist information about the patient’s body awareness including body 
consciousness and body management. In practical use this has two purposes, as to describe 
dysfunctions as components and to measure change between different ratings in order to 
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evaluate the effect of treatment. All items in the scale have the scale-steps 0-3, where half-
steps should also be used, “0” represents the healthy situation and “3” an extremely 
pathological. The evaluator had to be educated in the scale which also is interrater reliability 
tested [45]. The original version of BAS scale is in Swedish language.   
Dementia assessment. Gottfries-Bråne-Steen geriatric rating scale (GBS) [46] is 
an assessment of the dementia syndrome and was used for measurements of dementia 
symptoms. The scale is divided into 3 subscales measuring impairments of motor 
performance (6 items), intellectual (11 items) and emotional (3 items) impairment and a 
fourth subscale measuring six symptoms such as confusion, irritability, anxiety, agony, 
reduced mood, and restlessness. The intellectual subscale measured impairment of orientation 
in space, orientation in time, personal orientation, recent memory, distant memory, 
wakefulness, and concentration; inability to increase tempo, absentmindedness, long-
windedness, and distractibility. The emotional subscale measured emotional blunting, 
emotional lability, and reduced motivation. The motor functions measured motor 
insufficiency in undressing and dressing, motor insufficiency in food intake, impaired 
physical activity, deficiency of spontaneous activity, motor insufficiency in managing 
personal hygiene, and inability to control bladder and bowel. The GBS scale have seven steps 
and are used to score impairment and symptoms and score 0 - 1 is considered normal, > 2 - 4 
moderate impairment  >4 - 6 severe dysfunction. The scale has been revised and translated in 
about 20 different language and is reliability and validity tested [47, 48, 49]. The motor 
performance part of the GBS scale has good correlation with Katz and Akpom; ADL index 
[50].  
Laboratory tests. Both blood samples and cerebrospinal (CSF) examinations were 
made.  
Cerebrospinal fluid (CSF) is produced in the brain and can be therefore considered to be a 
window to the brain.  Analysis of CSF provides information of the level of the given 
ganglioside GM1, of possible damage to the blood brain barrier (BBB), determination of 
antibodies to gangliosides, as well as about inflammatory or infectious processes in the brain. 
Examination of CSF biomarkers is important in treatment of patients to assess in vivo 
pathology. These biomarkers were e.g. as available and used for examinations of: cytology, 
monoamine metabolites HVA, 5-HIAA and HMPG (monoamine systems is one of the 
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cornerstones of biological psychiatry), corticotrophin-releasing factor, neuropeptides as DISP, 
NPY and somatostatin. Methods for the biomarkers related to AD as Aβ 1-42, T-tau and P-tau 
were not available at the time of this study. 
 Blood tests included complete haematological status, electrolytes, kidney, liver and thyroid 
function tests, vitamin B12 and folate levels. Further was a determination of specific antibodies 
to GM1 and of protein in serum, which is a part of check of the BBB.  It also included test for 
normal IgG index for detection of immunoglobulin production in the brain, and to exclude 
thyroid disorders, hyperparathyroidism and vitamin deficiency. 
Brain imaging. Magnetic resonance imaging (MRI) can measure atrophy with high 
accuracy, also in specific parts of the brain as the hippocampus. Computed tomography (CT) 
can visualize both treatable condition such as subdural haematoma and also estimate degree of 
brain atrophy. It is generally known, that the brain in AD there are a degree of ventricular and 
cortical changing [51, 52].  
Single Photon Emission Computed Tomography (SPECT) can be used to measure cerebral 
blood flow. SPECT can show signs of focal cerebral lesions, but not with high accuracy. This 
technique can identify the reduction in metabolism and cerebral blood flow (rCBF). In AD a 
temporo-parietal reduction is usually seen.  
Electroencephalography (EEG) can show changes in electrical activity indicating focal 
cerebral lesions and used in this study. An analysis prior to and after the treatment of the 
computer-generated EEG power spectrum can confirm changes. These changes of activities, 
frequency, and/or irregular firing patterns over the courses of drug infusion in different areas, 
are important findings of the pathological pattern occurring in AD.   
Results made on the basis of through clinical examinations for the clinical diagnosis of AD 
may be weighed together with the information gathered from supplementary investigations 
such as brain imaging, EEG and laboratory tests for evaluation of the disease [16].  
Global treatment efficacy and side effect assessment. Clinical 
Global Impression (CGI) [53] is a global clinical rating scale, which documents the treatment 
efficacy and side-effect. The main groups are: Severity of illness, Global improvement, 
Efficacy index, and Therapeutic effect with Side effects. The assessment on this scale should 
be performed independently of the assessment on the cognitive battery. The UKU side-effect 
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rating scale is from Scandinavian Society of Psychopharmacology Committee of Clinical 
Investigations [54]. This scale is made up by 48 different symptoms, used in this study. Both 
the symptoms themselves and the extent of the symptoms (range 0-3) are defined. For each 
side-effect, the causal relationship to test treatment is evaluated. 
1 .3 Clinical symptoms: early-onset, mild, moderate AD 
Signification and empirical research studies 
Memory. The impairment of short-term memory is one of the earliest and most prominent 
symptoms of the disease. Short-term memory refers to performance in memory tasks over a 
very short period of time [55]. It is believed that the information resides briefly in an active 
memory state and then is either recalled directly, lost or encoded further for transmission to 
the long-term memory, i.e. for more permanent storage.  
The long-term memory is divided into episodic, semantic and procedural memory, all of 
which are of important in daily living [56]. 
The episodic memory deficit is pronounced early in the disease, probably due to brain 
changes in areas critical to episodic memory [57]. This memory draws on a widespread 
network of brain structures; thus, changes at multiple sites in a large distributed network are 
capable of disrupting performance [see 58].  Results from studies indicate that patients with 
AD in the early onset of the disease are able to utilise cognitive support in episodic memory 
task. However, they need more support than the healthy aged to show improvement. They 
need support which had to be provided during both encoding and retrieval, such as in a study 
using motor activity [59].  
Semantic memory refers to the component of long-term memory, which represents our 
knowledge of objects, facts, as well as words and their meaning [56]. Results from a study 
indicate as follows: mildly and moderately demented AD patients’ ability to utilize cues 
following a motoric encoding may be preserved later in the disease than they are able to 
utilize cues after a semantic encoding [60].            
Procedural memory, the learning of motor tasks, undergoes little decrement until the late 
stages of the illness [13]. It is important to maintain this resource of the patient, e.g. 
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enhancing self-esteem, when carrying out tasks independently and of social activities in daily 
intercourse. 
Aphasia. Early in the course of AD the reduction in functions of speech is observed which 
was followed with a pronounced deterioration of speech faculty. In the second stage this 
deterioration is followed of the aphasic disturbances which all is one of the chief symptoms as 
proposed by Sjögren and his colleagues [30] in their three clinical course of AD.  
Communication. Evidence for communication disruption early in the course of AD has been 
provided [61]. In a review, Emery [62] summarised studies and found that in patients in the 
early stage of AD: vocabulary became impoverished, speech circumlocutory, and that 
confrontation naming was progressively impaired. It was suggested that the aphasia profile in 
AD should be named “Alzheimer aphasia”. In her opinion, the relationship between semantics 
as a dimension of language (analysis and interpretation of meaning) and semantic memory on 
the theoretical front needed to be worked on. 
Naming errors have been suggested, as including in analyses, that a major factor behind the 
naming problems in AD is a semantic memory loss [63]. Impaired naming has been 
commonly seen as a prominent deficit in AD, [64, 65] and that anomia is in part due to loss of 
lexical semantic information [66].  
Pragmatic ability has to deal both with lexical and memory function. Within the social context 
of the person with AD includes the conversational partner, who greatly can influence the 
person’s with AD ability to produce discourse [67].  
Reading disorder occurs in the early stages of the disease. In reading, the patients are quite 
often able to read words but frequently fail to comprehend their meaning. Reading therefore 
appears to occur via the lexical rather than the semantic or sub lexical routes [68].  
Writing deficits appeared to be a more sensitive indicator of language dysfunction in AD than 
anomia [69].  
Oral spelling has in AD been found to be more impaired than written spelling [70]. In 
calculation procedures the difficulties may already appear at an early stage of AD [71].  
Executive processes. Executive functioning refers to a heterogeneous and wide-ranging 
set of cognitive operations, including allocation of attention, inhibitory control, hypothesis 
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generation, and self-monitoring, as well as other skills believed to be governed by the 
prefrontal cortex [72, 73].   
Planning and function in complex situations, e.g. executive function tasks primarily required 
concurrent manipulation of information, is reduced early in Alzheimer’s disease [74]. These 
impairments in the capacity, to combine performance on two simultaneous tasks, have a 
considerable impact on function in AD. Executive processes are clearly a mixture of control 
mechanisms.  
Included in the executive processes are selective attention, scheduling of different mental 
operations and the ability to co-ordinate mental activity in a way that facilitates problem-
solving activity. 
Later, Collette et al. [75] suggested deficits in executive functioning performance in AD as: 
the inhibition abilities and the capacity to co-ordinate simultaneously storage and processing 
of information. The results also confirm that some deficits may be in the first stages of AD. 
Apraxia is defined as loss of ability to carry out familiar purposeful movements, difficulty 
making voluntary gestures, all in the absence of motor or sensory impairments. The rhythm 
and the co-ordination of the movements, which is necessary for normal gait, were in the early 
stages of AD observed by Sjögren and his colleagues [30]. Patients with mild AD had 
impaired postural control as compared to healthy subjects which showed that this control is 
affected already at mild stages of AD [76].  
Ideomotor apraxia (impairment in the selection of the elements that constitute a movement) 
and ideational apraxia have been evaluated in different stages. In a study with 142 patients 
with dementia, 35% of apraxia was found in the mild stage, 58% in the moderate stage, and 
98% in the severe stage of dementia. Ideomotor apraxia was apparent in mild dementia when 
considered separately [77]. Another study confirmed these results [78]. 
Motor disturbances are usually associated with mental disorders. A way of limiting 
unnecessary motor deficiencies in everyday functional performance is the use of the BAS 
scale (Body Awareness Scale) [44] that describes and measures the patient’s body awareness, 
body consciousness and body management changes. This scale was used over time in a pilot 
study in early-onset mild to moderate AD and the result showed improvement based on the 
decreased observed and examined items [79]. However, aspects of the impact on functional 
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performance were found in a study in which activity level and postural control were 
evaluated. The patients with mild AD were found to be less active in e.g. social outings, car 
rides, household activities and car maintenance and had lower scores on a balance scale 
(timed up-and-go test; walking-in-figure test) compared with healthy elderly persons [80].   
Myoclonus (shock-like contractions of a muscle or group of muscles) was rarely observed in 
patients with mild AD in a multicentre study [81].   
Agnosia. Agnosia is a class of recognition disturbances that are confined to a single 
modality.  Agnosia refers to the inability to recognise the import of sensory impressions; the 
varieties correspond with several senses and are distinguished as auditory, gustatory, 
olfactory, tactile and visual. In Agnosia there is an inability to recognize objects using one of 
the senses, even though the sense in question is intact. Perception is the conscious mental 
registration of a sensory stimulus, to be perceptive. Depth perception is the ability to 
recognize or relative distance to different objects in space. Recognition is the act of 
recognizing or state of being recognized.  
Prosopagnosia is the inability to recognize faces. This is due to damage to the underside of 
both occipital lobes but yet having the knowledge that a face is a face and can identify the 
facial parts (nose, mouth, etc). Noted in a study was that in about one fourth of the mild-to 
moderate patients with AD had person- identifications disturbances. Most common was 
transient, sporadic misidentifications and least was prosopagnosia [82].   
Visual selective attention is impaired at the stage of disengaging from the target, divided 
attention appears to be particularly impaired, while phasic arousal appears to be only minimal 
affected in the early stages of AD [83, 84].   
The majority of patients with AD, who exhibit prominent but selective visual impairments, 
appear to have deficits in visual selective attention.  
Visuospatial symptoms. Spatial disorientation is common in the early course of AD. 
The patients get lost in their surroundings, placing objects in inappropriate locations, and fail 
to produce more elementary figures [30, 85, 86]. Coslett and Saffran [87] found that 
Alzheimer’s disease may selectively disrupt specific visuospatial processing mechanisms. 
These are including visual selective attention, process-mediating object recognition, and the 
spatial map (registered object localisation, object dimension). Inherent in the attention process 
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performance were found in a study in which activity level and postural control were
evaluated. The patients with mild AD were found to be less active in e.g. social outings, car 
rides, household activities and car maintenance and had lower scores on a balance scale 
(timed up-and-go test; walking-in-figure test) compared with healthy elderly persons [80].  
Myoclonus (shock-like contractions of a muscle or group of muscles) was rarely observed in 
patients with mild AD in a multicentre study [81]. 
Agnosia. Agnosia is a class of recognition disturbances that are confined to a single 
modality.  Agnosia refers to the inability to recognise the import of sensory impressions; the 
varieties correspond with several senses and are distinguished as auditory, gustatory, 
olfactory, tactile and visual. In Agnosia there is an inability to recognize objects using one of 
the senses, even though the sense in question is intact. Perception is the conscious mental 
registration of a sensory stimulus, to be perceptive. Depth perception is the ability to 
recognize or relative distance to different objects in space. Recognition is the act of 
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are the ability to attend to sensory inputs, selective or screening out other competing inputs 
and split or divided attention between more than one tasks [84]. Of interest are arguments 
presented by Frith [88], who associates attention not with a single resource pool but with two 
separate functions, that is: selectivity of information for processing and capacity limitations.  
Visual field loss [89] and inability to perform figure-ground discrimination tasks as well as 
recognition of tasks that are visually presented in AD have been reported [90]. Pathological 
changes in the primary and association cortex have been reported in AD [91, 92, 93].  
1 .4  Gangliosides 
Gangliosides are plasma membrane lipids, glycosphingolipids containing sialic acids, with the 
hydrophobic portion embedded into the membrane and the carbohydrate portion extending 
into the extracellular environment [94], originally found and named in 1942 by Klenk.  The 
ganglioside concentration is much higher in the brain than in other organs, highest in adult 
cerebral and cerebellar grey matter [95]. Loss of gangliosides in brain in Alzheimer’s disease 
was first reported 1965 and is an indication of reduced amount of plasma membrane in the 
brain [96].  
The research of possible biological function of gangliosides has been ongoing for a long time.  
charged ions, their existence in membrane clusters, and also the involvement in cell 
recognition, adhesion and differentiation [97, 98, 99]. Further research is of their 
neuronotrophic (concerned primarily with survival and maintenance of the neuron) and 
neuritogenic activity (involving of neuronal processes) [100] as well as their more informed 
use as neuro-therapeutic drugs [101].   
Quantitative estimation of sialic acid and quantitative estimation of gangliosides in senile 
human brains was 1957 performed in ongoing ganglioside investigations at our laboratory. 
Some years later a nomenclature for separation of human brain gangliosides, involving its 
four major gangliosides: GM1, GD1a, GD1b, and GT1b, was proposed by Svennerholm [102, 
103, 104], followed by the evidence that ganglioside GM1 in CNS is concentrated in the pre-
and postsynaptic membranes of the synaptic terminals, in the synaptic junction [6].  
Such as these which are attributed to their extracellular oligosaccharides, interaction with positively 
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Treatment with ganglioside GM1  
Positive effects of GM1 treatment on neuronal damage in the CNS and of nigrostriatal 
dopanergic neurons have been reported in animals [105, 106, 107,108, 109]. GM1 has given 
the best amelioratory effect of the major gangliosides. Similar results of experimental cerebral 
ischemia indicated, that GM1 can reduce the extent of infarct volume and neurochemical 
deficits associated with the ischemic event [110].   
In human studies, at this time, ganglioside GM1 was used in diseases as stroke and in 
treatments to enhance recovery after central nervous system (CNS) injury [111].   
According to the treatment of stroke, the results exhibited neurological improvement [112].  
In acute cerebral ischemic stroke, treatment with GM1 showed evidence to produce 
significantly greater degree of neurologic improvement than placebo treatment [113].  The 
beneficial effects of GM1 treatment on the damaged dopamine system in various animal and 
in vitro models went on to assess GM1 treatment in Parkinson’s disease [114].   
In Alzheimer’s disease, with use of parenteral administration, the result of ganglioside GM1 
treatment offered no overall symptomatic benefit to the patients [115]. This negative result 
was also shown of 3 months GM1 treatment [8] although a high level of labelled GM1 in 
serum. However, no detection of GM1 in the cerebrospinal fluid (CSF) indicated that GM1 
not had passed the blood-CSF barrier in that study. Some years later again the result in a study 
in AD showed that parenteral GM1 treatment failed to produce improvement in cognitive test 
[116].   
Intracerebroventricular administration of ganglioside GM1 is a new way to overcome the 
blood-brain barrier by an administration of a drug directly in the brain. This method was 
developed in a pilot study [117] in our treatment project for patients suffering from early onset 
AD. This means a treatment with an operation of an implanted system to get continuously 
infusion of GM1 into the brain. The surgery included implantation of catheters connected 
with a drug pump. The drug pump was to be refilled with subcutaneous injections. These are 
documented in this thesis with start in Paper I.   
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Amyloid beta-protein and gangliosides 
 GM 3 and GM1 are newly suggested to accelerate the deposition of the amyloid beta-protein 
as amyloid angiopathy and senile plaques, respectively, in the Alzheimer brain [118]. These 
observations indicate that neuronal gangliosides are involved in the accumulation of 
circulating beta-amyloid to form complexes that are expressed in AD brain. In spite of this 
gangliosides have been shown to improve brain function. These aspects, however, points to 
the need of future studies of the therapeutic potentials of gangliosides in AD [119].   
At the time of the study, acetylcholine esterase inhibitors or the partial glutamate inhibitor 
memantine were not registered in Sweden and there was no specific treatment of Alzheimer´s 
disease.  
1.5 Perspectives on treatment of early onset mild to 
moderate AD 
In AD, degenerative changes are accompanied by a reduction in a number of mental 
functions. In all, they overall impact on the patients’ participating in daily living.  
Mental activity is reflected in activation of different brain areas [120]. Specific lesions of the 
brain produce specific alterations in behaviour, and these are reflected in characteristic 
functional changes in the brain [121].   
The clinical fact, that AD patients with parietal symptoms damage are not all the same, means 
there is variability in the expression of their cognitive problems. Individual design is then a 
reasonable approach of treatments to overcome disablement caused by impairment, activity 
limitations and participation restrictions of the patients. 
Research findings, where the techniques to map brain activation in relation to mental 
performance have been used, suggest that the pattern of activations of the brains is changed in 
patients with mild and moderate AD. The results also suggest that it would be possible to use 
a patient’s remaining capabilities in therapeutic treatments to overcome deficiencies in lost 
functions.  
Another pattern is also formed during memory tasks [122], whether other frontal and non-
frontal areas are utilised [123] in early-onset AD compared with normal adults, and by 
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forming new networks [124]. These findings points to plasticity in the brain, suggesting that 
mental activation can modulate both aspects. The results suggest mechanisms by which it can 
be possible for the AD brain to compensate for neurodegenerative changes.  
Neuroplasticity allows to compensate for disease and to adjust the neuron activities in 
response to new situations or to changes in their environment. The brain's ability to reorganize 
itself by forming new neural connections remains throughout life. In order to reconnect, the 
neurons need to be stimulated through activity [125].   
The brain activity in the cortical sensory areas in Alzheimer’s disease is comparably little 
affected by the neural degeneration [11, 12]. Further, patients with AD have been found to 
have preserved learning of motor procedures [13]. These evidences open for use of the 
patient’s perception to compensate other impairment in performance of tasks, activities, and 
properties of things.  
Clinical studies 
Cognitive stimulation is often mentioned in studies of training in dementia. In one of these 
studies, the results of 5 weeks in 10 sessions showed no change in the ADL scale, no 
improvement in behaviour but improvement on MMSE.  This programme relied strongly on 
mental imagery [126].     
Memory training in form of problem solving solely of the given material and with use of 
conversation was done one hour a day, six days a week, by family members.  The results 
showed that the patients maintained the problem-solving skills over a period of 8 months 
[127].   
The spaced retrieval technique is another form of memory training designed to teach a patient 
to use a memory aid. This involves active attempts to recall information over expanding 
intervals of time. Improvement was found when appropriate support was given [128].   
Procedural learning is relative well-preserved in AD. The activities in a study by Zanetti et al. 
[129] were basic (e.g. washing face) and instrumental (e.g. reading a brief sentence) 
performed during 3-week training (1 h/d, 5 d/week). All ten patients showed improvement in 
their performance of the tasks trained.  
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Therapeutic activities in a kit called the BAG (Be Active with Games) were provided to be 
used at home in a study by Hutchinson & Marshall [130]. The BAG had been developed for 
individuals in all stages of AD. The kit, containing 20 therapeutic activities, was found useful 
by some of the 21 caregivers while for others it was an additional burden.  
Specific computer-based training with use of a touch-screen-function on a monitor was 
developed for four patients with mild to moderate AD. They were instructed to by step 
touching correct screen areas to complete the task. About fifty to 100 photographs from their 
surroundings and biography were taken. Training frequency was 3-4 times per week, two 
training phases and each lasting 4 weeks. No significant changes were seen although the 
levels of motivation were high. There were, however, signs of emotional activation. Three 
patients were able to maintain parts of the trained skills over a period of 4 weeks [131].  
1 .6  Available specific therapies in dementia 
Considering use of activation and training programme 
Several nursing methods have been suggested in the care of patients with dementia. 
Evaluation of studies in meta-analysis may give a suggestion of benefit or perhaps warning of 
problem with a therapy. There is no evidence for positive effects of a number of different 
therapies e.g. Reminiscence therapy, Validation therapy, Music therapy, Multisensory therapy 
(Snoezelen) according to reviews in the Cochrane Library [132] or SBU systematic review 
[133]. It is also sometimes hard to see the degree of dementia of the included patients. The 
reason may be that the therapy covers all stages and thus may well be used in all stages of 
dementia. However, these therapies are not applicable on the patients with early-onset, mild to 
moderate AD in this thesis, and will therefore not be discussed.  
Reality orientation. By conducting a systematic literature review, the effectiveness of 
classroom reality orientation (RO) of patients with dementia, AD, was evaluated [134]. The 
evidence of their meta-analysis indicates that RO has benefits on both cognition and 
behaviour for dementia suffers but no evidence of long-term effects.  
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Specific Reminiscence programme was included in the SBU reviews for patients in 
mild dementia. This intervention was designed as an individual treatment. Significant 
improvement was found of social wellbeing [135].  
Physical activity programmes, were evaluated in the Cochrane Library [136]. 
Insufficient evidence was found to determine the effectiveness in managing or improving on 
cognition, function, behaviour, depression, and mortality in people with dementia. However, a 
meta-analysis (more than 300 articles) on the effects of different form of exercise training, in 
SBU systematic review, found increased fitness, physical and cognitive function and positive 
behaviour . The subjects were 65 years of age or older including dementia, Alzheimer’s 
disease and related cognitive impairments. Exercise yielded statistically significant positive 
effect [137].  
1 .7  Therapeutic and medical treatment
Empirical studies 
Pharmacological treatment. There are three cholinesterase inhibitors in clinical use. 
These drugs increase acetyl choline by inhibition of the degradation. They are registrated for 
use in mild to moderate Alzheimer's disease. Despite the slight variations in the mode of 
action of the three cholinesterase inhibitors there is no evidence of any differences between 
them with respect to efficacy. Addition of memantine can give slight improvement [138]. 
Long-time treatment with cholinesterase inhibitors and memantine prolongs the time when 
referral to nursing home is necessary [139].  
Cognitive stimulation programmes benefit cognition in people with mild to 
moderate dementia over and above any medication effects according to consistent evidence 
from multiple trails [140]. One form of mental exercise is described as cognitive stimulation. 
This involves a range of activities, including discussion of past and present events and topics 
of interest. The review included 15 trails. The findings suggested that cognitive stimulation 
has a beneficial effect on the memory and thinking test scores of people with dementia.   
Rehabilitative intervention for patients with AD and their caregivers for 4 months, in 
60-minutes sessions a week, were of the effect evaluated by Onor and her colleagues [141]. 
All patients had mild to moderate AD, were aged 60-80 years, and had been receiving acetyl 
cholinesterase inhibitors for more than six months. The results showed that the patients with 
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mild to moderate AD had a more stable cognitive status and improved mood. For the 
caregivers, the efficacy of the psycho educational program was reported in terms of increasing 
and preserving their coping skills and enhancing their perception of the value of support 
groups. 
A computer-based cognitive rehabilitation program for patients with mild AD was 
carried out in 4-week periods. The patients were medical treated with acetylcholinesterase-
inhibitor (AchE-I) treatment at a stable dose (5 mg/day for donepezil and 6 mg/day for 
rivastigmine). A single session about 13-45 minutes was held on 4 days per week, covered a 
4-week period. There was then a break, which lasted 6-2 weeks before next (same) single 
session. The patients as a group showed a significant improvement on mini mental scores, in 
areas of verbal production, and on executive functions but not in affective and functional 
areas [142].   
Intensive reality orientation therapy (ROT) was the target of the cognitive 
rehabilitation, with active participating of the caregiver, in the evaluation of the efficacy of 
the combination of donepezil therapy. The donepezil therapy was combined with regular daily 
45-min class meetings for 3 weeks with active participating of caregivers all the time. This 
was compared with donepezil treatment alone. The patients were in the mild to moderate 
stage of AD. Test was at baseline, at the end (3 weeks), and after 2 months of follow-up. The 
results of the combined therapy showed significant improvement in MMSE and ADAS-Cog, 
without changes in impaired ADL and instrumental ADL. There were no significant changes 
in MMSE in drug-only treated patients after 3 weeks, with a non-significant tendency to 
improvement in ADAS-Cog. Their results suggest benefit of an intensive ROT program that 
seems to be maintained as far as ROT is continued by the caregiver [143].  
Language enriched physical fitness interventions provided by undergraduate 
students in Arizona University, have showed promising results [144]. The 24 participants had 
mild-to moderate form of AD, aged 54-80 year and with MMSE score 15-29 (“AD Rehab 
group”). Socialization experiences consisted of supervised volunteer work and cultural or 
recreational activities.  
In this student-treatment provider concept, the study participants were 24 individuals of which 
11 participants completed 2 semesters of treatment (1-year completers), 5 patients completed 
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4 semesters (2-year completers), 4 patients completed 6 semesters (3-year completers), and 4 
completed 8 semesters (4-year completers).  
In comparisons with the “CERAD sample”, a slower rate of decline for the “AD Rehab 
group” was suggested. The stabilization of global and cognitive performance was not apparent 
after completed only 2 semesters. However, after 4 or longer semesters the cohorts showed no 
significant between-year changes after their first year. This was in measuring global 
functioning and on 5 or 6 of the cognitive and language measures.  
1 .8  Prospects behind development of SATprogramme 
Nursing and care within health and environment 
The concepts inherent in nursing are generally said to be the individual, nursing, health and 
environment  [145]. As health and disease are mostly associated with objective physiological 
and psychological measures, Brenner and his colleague [147] chose to use the terms 
”wellbeing” and “illness”. Wellbeing reflects the lived experience of health, and illness, the 
lived experience of the disease.   
In Travelbee’s nursing theory [147], care can be seen as an activity. The purpose of nursing is 
to assist an individual, family or community to prevent or cope with the experience of illness 
and suffering and, if necessary, to find meaning in these experiences (health teaching) [147]. 
The purpose of nursing is achieved through the establishment of human-to-human 
relationship. This is a mutually significant experience, a reciprocal process. The responsibility 
for establishing and maintaining rests with the professional nurse practitioner. The 
relationship is characterized by rapport and includes all elements necessary: the original 
encounter, emerging identities, empathy (is a mutual understanding), and sympathy (see page 
119, 136).  
Communication is viewed as a process which can enable the nurse to establish a human-to-
human relationship and thereby fulfil the purpose of nursing. Every interaction affords an 
opportunity to meet the ill person’s nursing needs. About the concept communication, a major 
belief of her work is :”...that it is the task of the professional nurse practitioner to plan, direct 
and guide purposefully the interaction with the ill person in such a way as to fulfil the purpose 
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of nursing” (page 93).  Travelbee avoided using the term patient-nurse, which may come from 
her own experience as a psychiatric nurse practitioner, teaching psychiatric nursing or as a 
director of graduate education [148]. Concept of Travelbee is springboards in the thesis. 
Care as a structure process is on the basis of four phases, in which Tronto [149] distinguishes 
four ethical elements of care. These are attentiveness (being open to the needs of others), 
responsibility (for changing problematic conditions), competence (being competent, otherwise 
refraining from action) and responsiveness (respond to each other’s expressions during 
caregiving/receiving. The activities performed may then be regarded as a process of 
interaction, an assessment of needs between persons and in a social context.   
Health and environmental influence is in nursing a prominent concept. Florence Nightingale 
had it as a core concept in nursing and she had health as grounded in the environment. She 
thought disease was a reparative process. The nurse should manipulate the environment, 
helping the diseased patient at least to live a better life until death (see [150]). King [151] 
viewed health as a continuous adaptation to stress in the internal and external environment in 
order to achieve the maximum potential for daily living. Therefore, essential for nurses is an 
understanding of the ways that human beings interact with their environment to maintain 
health. 
Since Alzheimer’ disease is at present incurable, looking at concepts of nursing in this way is 
relevant. ?? it emphasises the experience of meaning in the situation rather than ?????
related to the curing of the disease. Concepts of Travelbee [147] and Tronto [149] are 
springboards in Paper I-V. 
Patient - the environmental hierarchy and interaction                     
When humans encounter and perform in various environments, a process of interaction 
occurs. This process is between persons and environments, and environmental factors (which 
influence this process) and is named “layer” as examined by Barris et al. [152].  
The individual’s choice of which environment to explore involves influence. Such is by 
constraints, values, and interest but are also volitional.  
Arousal, an “internal state with subjective and physiological manifestations” [152], is said as 
a concept which connects volitional traits with properties of the environment.  
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The central “layer” around the person is objects which is the materials of our daily life. These 
are: availability (refers to presence); complexity (reflects skill and leaning required for its 
use), flexibility (pertains to potential of using it in many variety way) and have a symbolic 
meaning (e.g. objects become symbols of power, prestige, independence). Next “layer” is 
tasks e.g. everyday tasks, and thereafter, the social groups and also organizations with number 
of people and function. The final “layer” is culture which is shared by a group. Together these 
“layers” represent an environmental hierarchy.  
These “layers” influence the individual’s decisions both to encounter and performances in 
these environments. A modified content of Roann Barris et al. [152] recommendations is 
springboard in Paper III.   
Patient - environment and connection to individual needs  
Demented patients need increased environmental clarity to compensate for cognitive and 
functional deficiencies and also adjusted surrounding for psychological wellbeing. A 
congruence model of person-environment interaction has been proposed and discussed in a 
conceptual model by Kahana [153]. It is a congruent model of environmental characteristics 
and individual needs. That is in the role of understanding the impact of environmental settings 
and contribution to wellbeing.  
Two broad areas of congruence were discussed. These are dimensions based on 
environmental differences and also dimensions based on individual differences. 
In the segregate dimension, the concept may refer to the heterogeneity or homogeneity of the 
setting. This is for example level of function and may contrast living or participating with a 
group of persons much like oneself/ different from oneself. The congregate dimension refers 
to closeness, which is the degree of privacy possible to get in the setting. It is also the 
institutional-control of residents, which refers e.g. to the degree of tolerance of resident 
autonomy that is tolerated. According to Kahana (page 102) it may be expected that along 
these dimensions should lead to a sense of wellbeing, satisfaction, and adequate function in 
the institution. The congruence model of Eva Kahana [153] is springboard in Paper III.   
Patient - environment demands on functional capability      
Environmental demands can create barriers which hinder task performance by demands to 
functional capabilities. Successful task performance is dependent on a match between task 
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These “layer” influence the individual’s decisions both to encounter and performances in 
these environments. A modified content of Roann Barris et al. [152] recommendations is 
springboard in Paper III.   
Patient - environment and connection to individual needs               
Demented patients need increased environmental clarity to compensate for cognitive and 
functional deficiencies and also adjusted surrounding for psychological wellbeing. A 
congruence model of person-environment interaction has been proposed and discussed in a 
conceptual model by Kahana [153]. It is a congruent model of environmental characteristics 
and individual needs. That is in the role of understanding the impact of environmental settings 
and contribution to wellbeing.  
Two broad areas of congruence were discussed. These are dimensions based on 
environmental differences and also dimensions based on individual differences.  
In the segregate dimension, the concept may refer to the heterogeneity or homogeneity of the 
setting. This is for example level of function and may contrast living or participating with a 
group of persons much like oneself/ different from oneself. The congregate dimension refers 
to closeness, which is the degree of privacy possible to get in the setting. It is also the 
institutional-control of residents, which refers e.g. to the degree of tolerance of resident 
autonomy that is tolerated. According to Kahana (page 102) it may be expected that along 
these dimensions should lead to a sense of wellbeing, satisfaction, and adequate function in 
the institution. The congruence model of Eva Kahana [153] is springboard in Paper III.   
Patient - environment demands on functional capability         
Environmental demands can create barriers which hinder task performance by demands to 
functional capabilities. Successful task performance is dependent on a match between task 
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demands and human capabilities. By using the purpose to reinforce independence, the 
winning may thereby contribute to wellbeing among people.  
A modified technique of Human Factor, which implies a step-by step task demand analysis, 
has been demonstrated by Czaja et al. [154], which is a method from Human Factors 
Engineering. The model conceptualizes change as occurring in multiple stages. This means to 
break a task or activity into subtasks or steps. This action, with defining the cognitive and 
physiological performance requirements, is involved in each kind of step - to reach the goal. 
The modified technique of Czaja et al. [154] is springboard in Paper III. 
Patient - environment contact in upholding stimulation    
Frings [155, 156] described that in the signal transduction process, each sensory cell detects 
specific stimuli and the nerve impulses are conveyed to and provide CNS with vital 
information about the body and its environment. When it comes to cortex, the complex 
information is then integrated and can be used to generate sensible behaviour why, in that 
way, nervous system thresholds contribute to individual’s behavioural repertoire by this 
provided information. Therefore the equipment in form of different colour, sizes and tools are 
a part of stimulation which provides in the training setting, important stimuli.   
Schultz [125] provides empirical support for the proposition that man needs constantly 
varying forms of sensory stimulation to function adaptively in his/her environment. This form 
of function is of importance in treatment of patients with Alzheimer’s disease (AD).  Schultz 
[125] provided in his book evidence of productions, such as of physiological effects with 
threshold changes, cognitive and learning effects, perceptual and motor effects in sensory 
restriction research. In the part of sensory variation as reinforcement, his propositions do 
demonstrate the reinforcing effects of a change in stimulation. Further that a change in 
sensory variation can have reinforcing properties leading to the learning of instrumental 
behaviours (page 28). For adult was also that “... effective functioning depends on the 
continued maintenance of contact with an appropriately rich sensory environment “ (page 
194).  The brain’s anatomy is immensely complex and the structure and interconnections of 
its parts are still not fully understood. By allowing various form of stimuli to reach the 
patients’ senses they can experience and thereby put the remaining sense faculty into practice 
in performance of activities of daily living. In this thesis of practical performance during the 
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patient’s active participating, in both internal and external surrounding, Schultz proposition 
[125] is within the discussion in Paper III. 
Patient - expectations to use of remaining abilities 
Ability to perform tasks or an activity can be seen in the light of concepts used by Nordenfelt 
[157] in his outlining of what it means if a person is able to perform actions.  
Nordenfelt, his prerequisites or concepts is related to a set of circumstances. These are that the 
participant’s internal resource for performing the action is sufficient. These are also that it 
must be a practical possibility of performing the activity or task. The circumstance is also that 
there must be right opportunities. In this thesis, Nordenfelt’s contains of his outlining has 
been considered.  
From the patients’ point of view, based on that they are able to perform dependent or 
independent actions, it might be hard to always understand their own limits. A belief may 
have occurred before the start of the therapy. That might be that the instructor skill qualities 
should help them to solve problem and limit negative influence of circumstances within 
performance of daily activities.   
From the nursing care point of view, these prospects is reasonable and ought to be within the 
modifying or duties to hold each patient’s remaining capacity to perform tasks or activities, 
and further, to be related to a set of reasonable circumstances within the patient’s real social 
life. Practical possibility to perform activities should well be a part by providing specified, 
(regarding place and time) and explanation of all tasks in an exact and detailed way the. The 
right opportunity means to provide the patient by and use of a location in which it is easy to 
do the performance. This view is well a part within the equipped training setting provided and 
the patient is in that way seen to be provided with individual right opportunity.   
Right opportunity is important, as if there is no opportunity, this may induce the risk to fails. 
This risk is always there, as the presence of ability may vary especially in Alzheimer’s 
disease.  
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2   AIM   
Overall aim 
The overall aim of this thesis was to investigate and describe a training programme, within 
nursing aspects, for the impaired activity concomitant AD as a therapeutic treatment to assist 
in a innovative treatment with a continuous intracerebroventricular administration of 
ganglioside GM1 in the treatment for patients suffering from the early-onset, mild to 
moderate AD. 
The specific aims were: 
In Paper I: to elucidate how treatment with GM1 and home based activation and training 
influenced patients with early onset AD and spouses’ reaction to the treatment.  
In Paper II: to examine whether intracerebroventricular infusion of ganglioside GM1during 
one year, in conjunction with activation and training of the patients, could improve cognitive 
impairments in patients with early onset, mild to moderate Alzheimer’s disease.  
In Paper III: to describe the content and the individual design as well as the execution and 
outcome of a newly developed stimulation-activation-training (SAT) programme. 
In Paper IV: to extend the knowledge, from a close partner’s monthly perspective during one 
year, of everyday life with a partner suffering from early-onset, mild to moderate Alzheimer’s 
disease.  
In Paper V: to study the linguistic development within regularly performed language 
activities during one year of patients with early onset, mild to moderate Alzheimer’s disease. 
Development of nursing programme
28 
3   METHODOLOGY 
The background to this combined treatment strategy is a long time collaboration between 
basic and clinical researchers which started in our Experimental Neuroscience Section and 
Psychiatric Section, Sahlgrenska University Hospital-Mölndal in the sphere of dementia in 
neuropathology, neurochemistry, neuropsychological examinations and ganglioside 
investigations. Important to mention for this thesis are the basic ganglioside investigations, 
ongoing since 1950s [103] and development of the dementia scale, the GBS scale in 1980s 
[146].   
Table 1. Overview of participants and methods in the empirical studies  
Paper Participants Methods for data collection 
  I 
5 patients with 
early onset  mild-to - 
moderate  AD.   
Participating of 5 
spouses  
Neuropsychiatric-psychiatric-neuropsychological 
examinations, chemical-neurochemical laboratory tests, rCBF, 
CT, GBS scale, Activity scale, UKU scale, CGI scale, EEG, 
EKG, Daily Notes, interview  
   II 
5 patients with early 
onset  mild-to-
moderate AD  
(EAD) 
Physical, neuropsychiatric-psychological examination, 
chemical neurochemical laboratory tests, GBS scale,  UKU 
scale, CGI scale, CT, rCBF, MRI, EEG, EKG, interview, 
clinical observations 
 III 5 patients with EAD 
GBS scale, BAS scale, Activity scale, Norwegian Basic 
Aphasia test, clinical observations, Daily Notes 
 IV 
5 spouses to patients 
with EAD 
Clinical Global Impression evaluation form, clinical 
observations  
 V 5 patients with EAD Norwegian Basic Aphasia  Assessment, clinical observations 
3 .1 Subjects and methods in Paper I    
Paper I was the first study for intracerebroventricular infusion of ganglioside GM1 including 
neurosurgical procedures in treatment for patients with early onset AD, in combination with a 
home based activation programme during one year for each patient. The study was conducted 
at Department of Psychiatry and Neurochemistry at Sahlgrenska University Hospital - 
Mölndal  (SU/Mölndal). 
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3 .1 Subjects and methods in Paper I
Paper I was the first study for intracerebroventricular infusion of ganglioside GM1 including
neurosurgical procedures in treatment for patients with early onset AD, in combination with a 
home based activation programme during one year for each patient. The study was conducted 
at Department of Psychiatry and Neurochemistry at Sahlgrenska University Hospital -
Mölndal  (SU/Mölndal).
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The procedure before inclusion of the patient in the first study 
The patients were referred to the research team at SU/Mölndal (research centre) by general 
practitioners or other specialists at a distance from the research centre. These patients had met 
the referred criteria to have probable AD type 1(early onset) [16, 34], to be between 50 and 70 
years of age and to have at least 1 relative who was willing to and capable of participating in 
the training of the patient and in the evaluation of the treatment effect.  
These referred patients underwent a physical, psychiatric and neurological examination, a 
psychometric test, and extensive clinical chemical and neurochemical examinations by the 
research team (research centre) and computer tomography (CT), electroencephalographic 
(EEG), and regional cerebral blood flow (rCBF) measurement, in all to be used to baseline 
data.    
Baseline examinations 
The neuropsychiatric and neurological signs and symptoms were assessed according to the 
Stepwise comparative status analysis (STEP). This is a comprehensive observational 
instrument consisted of 35 items which are relating to various symptoms associated with 
dementia [36].  
The neuropsychological battery comprised MMSE, Fuld’s Object memory evaluation, 
Similarities and Digit Span, Face recognition test and Alzheimer’s Disease Assessment Scale 
(ADAS) assessments [42, 38, 39, 40, 41]. The degree of dementia according to the GBS scale 
was to be scored at most 4 on items measuring intellectual impairment. The patients were to 
have moderate intellectual deterioration, to allow for evaluation of the therapeutic effect. 
The score according to the Mini Mental State Examination (MMSE) had to be between 10 and 
24, preferably closer to 24 than to 10.  
Extensive clinical chemical and neurochemical examinations were analysed at clinical 
chemistry and clinical neurochemistry laboratory, Department of Neurochemistry, 
SU/Mölndal Hospital. The chemical examination, with use of collected blood sample, 
included complete haematological status, electrolytes, kidney, liver and thyroid function tests, 
vitamin B12 and folate levels.  
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The neurochemical examinations, in which samples of CSF was collected by means of a 
lumbar puncture, were used to determination of proteins in serum and CSF and cytology of 
CSF. The monoamine metabolites HVA, 5-HIAA, and HMPG [158, 159, 160] was 
determined in CSF as well as CSF neuropeptides, corticotrophin-releasing factor, DSIP, 
neuropeptide Y (NPY) and somatostatin [161]. Further, the CSF level of GM1 ganglioside 
was determined with using a recent developed ELISA method [A. Lekman, unpublished].  
Antiganglioside IgG and IgM antibodies were determined with an ELISA method [162] with 
the following glycosphingolipids antigens: GM1, GA1, GD1a, and GD1b [163]. SPECT was 
used to examination regional cerebral blood flow (rCBF), conducted at the Nuclear medicine 
section at Sahlgrenska University Hospital, Gothenburg.  
Exclusion criteria 
Presence of signs indicative of major medical illness or mental disease in addition to 
Alzheimer’s disease, history of inflammatory brain disease, multiple episodes of head trauma 
associated with sustained loss of consciousness, alcohol or drug abuse, concomitant therapy 
with CNS-active drugs that might markedly influence brain function were exclusion criteria.  
Included patients 
The five included patients scored 7-22 on the MMSE and were 54-70 years of age, based on 
the examinations before entry to the treatment study (base line data). The patients were four 
men and one woman, lived with their spouse, was Swedes, and had various education years. 
The patients had various level of the committed impairment due to AD. The most common 
impairment was sensory aphasia, visuospatial disturbance and reduced orientation ability. The 
least common were apraxia, body perception deficits, and loss of power of initiative. The 
patients were included at different time of the study start year. 
The participating spouses 
In accordance to the spouses’ willing to carry out a home based activation of the patients, an 
interview was performed including information about documentation of the in real time 
performance of the practical tasks and activities during the treatment year.   
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the examinations before entry to the treatment study (base line data). The patients were four
men and one woman, lived with their spouse, was Swedes, and had various education years. 
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All 5 patients signed a consent form before participating in the treatment project after detailed 
oral and written information. They were also informed that they could interrupt the treatment 
at any stage. The relatives who agreed to participate in the training and evaluation of the 
patient received the information together with the patient, and were also asked to give their 
written consent. The study was approved by the Ethics Committee, Faculty of Medicine, 
Gothenburg University, and the Swedish Medical Products Agency.  
The start of the one year treatments      
The study start was for each patient set to the surgery day (start: Day 0).  
All patients was at the study start fully supported by the research assistant from the 
psychiatric investigation ward at SU/Mölndal Hospital to the end of the surgery day at 
Sahlgrenska University Hospital, Gothenburg including the surgery aftercare days. 
The surgery 
Implantation of system for intraventricular ganglioside GM1 was conducted at Neurosurgery 
division, Sahlgrenska University Hospital. A brain surgery was used to install catheters in 
both lateral ventricles which were connected to a drug pump in the abdomen for continuous 
infusion of ganglioside GM1 into the brain. 
A craniotomy, including two bore-holes was made and coordinates for the targets in the 
lateral ventricles were calculated for the localisation of the catheters. Common shunt catheters 
were implanted and connected to reservoirs which were further connected to the infusion 
system in the brain. The catheters were connected to a single extension catheter tunnelled 
under the skin to meet the extension catheter from the drug pump. This was implanted 
subcutaneous in a pouch in the left fossa iliaca. The programmable pump was a round metal 
disk about one inch thick (25 mm) and three inches in diameter, weights about six ounces 
(170 g). The drug pump was filled with 17 ml of ganglioside GM1. The solution used for safe 
drug was 60 mg/ml in isotonic phosphate-sodium chloride solution, pH 7,4 (Sygen ®)[164]. 
The initial dose of GM1 was set on the basis of previous rat experiment to 30 mg/24h.  
The same neurosurgeon documented and carried out all neurosurgery and surgical treatment 
involved in the implantation of the infusion system as well as the included neurosurgery care 
at the psychiatric investigation ward at SU/Mölndal.  
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The refilling of ganglioside GM1 was subcutaneously timetabled once a month, 30 whole 
days (based on the rate of 0,5ml/24h). Accordingly there was 2ml of GM1 solution remained 
in the drug pump and the infusion was then interrupted. For safety reasons, the remaining 
solution was sent over time for bacteriological cultivation and for endotoxin determinations 
[162, 163, 164].   
The home based programme  
Around two weeks after the surgery of the infusion system the home based activation started 
gently. Daily activities, which were common in each patient’s home, was used to an 
individually adjusting to the patient’s need, wishes and field of interest. The patients were 
activated by the spouses who documented the performances. This was followed up and noted 
in the Daily Notes. The extended support for 2-4 hours by the research assistant was used to 
train and activate the patients and to instruct and inspire the spouses.  
The Activity scale (constructed by I. Karlsson for this project) was used as an instrument to 
enable presentation of level of independence/dependency of the patients’ performances 
according to score 0 (independent) - score 4 (cannot accomplish the activity or task). The 
scale was used by the spouses at home and by the research assistant. In a schema with name 
of tasks, date and assessment of the quality performances of their partner, the spouses hand 
over the documented performance at home to the research assistant.  
Daily Notes were used to regularly record clinical observations and assessments of the 
patient’s training, motivation and development by the research assistant. All contact between 
the patients, spouses and the research assistant was regularly documented and followed over 
time by use of Daily Notes.  
Clinical examinations and assessments 
An one-year timetable for each patient was used to follow the performed entry examinations 
(base line data) over time. When combination of examinations had the same day, the patient 
was inpatient on the psychiatric investigations ward at SU/Mölndal.  
Laboratory examinations were used to establish any abnormality and conducted at the 
research clinic. The chemical and neurochemical laboratory examinations (by blood sample 
and lumbar puncture), which started before entry study, (see Base line above) were timetabled 
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from the surgery (Day 0) and on days 30, 90, 180, 270, and 360. Extra determination of CSF 
level of GM1 ganglioside was to be included if a disturbance of the GM1 infusion was 
suspected.    
Clinical physical, psychiatric and neurological examination went on after the entry study (see 
base line data above) by the same observation of signs and symptoms associated with 
dementia following a schedule time tabled on the days 30, 60, 90, 180, and 360 to regularly 
evaluate disturbance.  
The psychometric test was after the entry study time tabled on days 30, 90, 180, 360 and 
carried out before noon on two occasions with one night’s rest between.  These were used to 
assess cognitive functions and treatment response. The GBS scale [46] measure dementia 
symptoms and was used to examine changes in intellectual and emotional condition and 
impairment of motor performance (inactivities of daily living/ADL). The GBS scale was used 
before treatment and every 2nd week for the first 3 months and then every month during the 
treatment period at home visits or at our research centre.   
The CGI scale was used to assess clinical global improvement and the UKU scale [54] to 
assess side-effect symptom, monthly documented by the research assistant and the 
psychiatrist.  
The examination with SPECT rCBF was used to perform measurements of the blood flow 
before and immediately after the treatment period and conducted at Sahlgrenska University 
Hospital. Ten normal subjects with mean age 61+ 14 (SD) served as controls. Reconstruction 
was performed as described by Larsson et al. [165] and relative quantification of the rCBF 
was conducted according to the maximum-minimum method [166].  
All these examinations were carried out by the same neuropsychiatrist, psychiatrist, 
neuropsychologist, research assistant, radiological-imaging experts, during the two year 
ongoing first study.  
Interviews with patients and relatives by an independent researcher were used to capture the 
experiences of the interviewees during the 1 year of treatment. The results from these 
interviews were to be use to compare with the research assistant’s assessment.   
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3 .2  Subjects and methods in Paper II 
Paper II was a treatment study, based on experiences from preliminary reports from our first 
study in Paper I, of ganglioside GM1 treatment complemented by a comprehensive training 
programme.    
Procedures before inclusion of the patients 
The patients had classical AD based on the NINCDS-ADRDA criteria for probable AD [34, 
16]. They were referred to the research team at SU/Mölndal from general practitioners or 
other specialists nearby the research centre.  
Before entry (base line), each patient underwent a physical, neurological and psychiatric 
evaluation, neuropsychological tests, rating with the GBS scale, clinical chemical and 
neurochemical examinations, computerized tomography (CT) and/or MRI (magnetic 
resonance imaging) scans, SPECT to assess rCBF (regional cerebral blood flow) in CSF, and an 
electroencephalography (EEG) examination.   
Neuropsychiatric examination by a STEP protocol was used to evaluate disturbance of mood, 
emotional function, psychotic or paranoid symptoms, symptoms of delirium, and symptoms 
related to the frontal lobe [36]. This was together with a neurological examination. A 
neuropsychiatrist and a psychiatrist carried out the neurological, psychiatric and physical 
examinations.   
The same set of neuropsychometric tests as in the Paper I was used to assess the patient’s 
baseline cognitive functions and was carried out by a neuropsychologist. These tests 
comprised MMSE, Fuld’s Object memory evaluation, Similarities and Digit Span, Face 
recognition test and Alzheimer’s Disease Assessment Scale (ADAS) assessments [38, 39, 40, 
41, 42]. The GBS scale was used to measure dementia symptom and assessed by the research 
nurse.  
Clinical chemical examinations included complete haematological status, electrolytes, kidney, 
liver and thyroid function tests, vitamin B12 and folate levels. Clinical neurochemical tests 
included measurement of proteins in serum and CSF. As common decreased monoamine 
metabolites in AD, homovanillic acid (HVA), 5-HIAA, and HMPG, and of somatostatin in 
CSF as well as CSF cytology was evaluated as described in Paper I [158, 159, 160].  
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GM1 levels in CSF were measured by means of resorcinol method [102]. Antiganglioside IgG 
and IgM antibodies were determined with an ELISA [162] with the following 
glycospingolipid antigens with ‘GM1 epitopes’: GM1, GA1, GD1a, and GD1b. The 
laboratory examinations were analysed at clinical chemistry and clinical neurochemistry 
laboratory, Department of Neurochemistry, SU/Mölndal. 
Exclusion criteria. Presence of signs of major medical illness or mental illness in addition 
to AD, history of inflammatory brain disease, multiple episodes of head trauma, alcohol or 
drug abuse, or concomitant therapy with CNS-active drugs that might markedly influence 
brain function were exclusion criteria.  
Entry criteria. The entry criteria were based on the base line examination. The age was set 
to 50-70 years; the dementia to be mild to moderate dementia (a score of 4 on items 
measuring intellectual impairment in the GBS scale [46]; the Mini Mental State Examination 
(MMSE)[42] score to be of 15-25 (preferable closer to 25),  and to have at least one relative 
willing to and capable of evaluating the effect of the treatment. 
Included patients     
The five included patients (Patient1 - Patient 5) were 54-70 years of age, were four women 
and one man. The duration of symptoms was 3 - 7 years. The MRI plus CT examination 
showed for Patient 1, 2, 5 that they had brain atrophy, Patient 4 had widening of lateral 
ventricles, and Patient 3 had no abnormal findings. Neurological symptom was shown in two 
patients of whom one had rigidity and subclonus, one patent had gait disturbance with 
hypokinesia. The MMSE scored 22 - 24.
Before start of the comprehensive training programme, complemented to the GM1 treatment, 
a home visit was provided by the instructor. This contact with the spouses and the patients 
was used to give information about this training treatment carried out at a nearby apartment.  
The patients lived nearby the research centre, had been married for many years, and were 
Swedes. The duration of the treatment was one year for each patient, who started at different 
times during the four years study period.   
All patients and their spouses signed consent forms after obtaining detailed oral and/or written 
information about the treatment. They were informed that they could interrupt the treatment at 
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any time. The study was approved by the Ethics Committee, Faculty of Medicine, Göteborg 
University, and the Swedish Medical Products Agency. 
The study start
The start of the treatment was set to the surgery day (Day 0). All patients were fully supported 
by the research assistant from the psychiatric investigation ward at SU/Mölndal to the end of 
the surgery day at the Neurosurgery ward at Sahlgrenska University Hospital.  
The surgery 
The surgery procedure was the same as in Paper I. All surgery in the implantation of the 
infusion system, from a craniotomy to connection with the outflow catheter of the drug pump, 
was carried out by the same neurosurgeon. This included neurosurgery aftercare, at the 
psychiatric investigation ward at SU/Mölndal. 
The dose of GM1 was set to 30 mg/24 h. When 2ml of GM1 solution remained in the drug 
pump the infusion was interrupted. For safety reasons, the remaining solution was sent for 
bacteriological cultivation and for endotoxins determinations [162, 163, 164]. The refilling of 
ganglioside GM1 was subcutaneously by the same psychiatrist, timetabled to be once a 
month.  
Clinical examinations and assessments 
A one-year timetable for each patient was used to follow the entry (base line) examination 
data during the treatment.  
On the day of surgery (Day 0), and on Days 30, 90, 180, 270 and 365 the chemical-, 
neurochemical laboratory examinations and the neuropsychological assessment were carried 
out. The clinical chemical and neurochemical laboratory examinations were performed to 
establish any abnormality. Extra measurement of GM1 levels in CSF was to be on days if a 
disturbance of the GM1 infusion was suspected. To collect CSF the patients were subjected to 
lumbar puncture. The neuropsychological examinations assessed cognitive functions and the 
treatment response over time was carried out before noon on 2 consecutive days by the 
neuropsychologist.   
In combination with these examination and assessments also the neuropsychiatric and 
psychiatric examination were carried out by the neuropsychiatrist and psychiatrist. Semi-
structural neuropsychiatric examinations were used to evaluate disturbances of mood, 
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emotional function, psychotic or paranoid symptoms, symptoms of delirium, symptoms 
related to the frontal lobe and a neurological examination [36].   
The GBS scale [46] was used to examine intellectual and emotional dysfunction and activities 
of daily living (impairment of motor performance) before treatment and every second week 
for the first 3 months and then every month during the treatment by the research nurse. The 
CGI scale [53] was used to assess clinical global improvement and the UKU scale [54] to 
assess side-effect symptom, monthly documented by the research nurse and the psychiatrist.  
When combination of examinations had to be performed the same day, the patients were 
inpatients on the psychiatric investigations ward at SU/Mölndal.  
The assessment of brain with CT and/or, MRI was done before the study start (base line) and 
after the one year treatment period to analyse tissue changes. Blood flow, rCBF, was 
measured with SPECT before and immediately after the one year treatment, conducted at 
Sahlgrenska University Hospital and data described by experienced appraisers. Ten normal 
subjects with mean age 61+ 14 (SD) served as controls. Reconstruction was performed as 
described by Larsson et al. [165] and relative quantification of the rCBF was conducted 
according to the maximum-minimum method described by us [166].  
 All examinations were carried out by the same neuropsychiatrist, neuropsychologist, 
radiologist, and research nurse during the ongoing four years of the treatment study.  
The training programme to assist GM1 treatment 
A new developed careful designed programme with Stimulation, Activation and Training 
(SAT programme), was used to maximizing the use of the patients’ identified areas of 
function and processes that are relatively unimpaired [167]. Cognitive, social and physical 
activities similar as performed within common daily living were used to be carried out twice a 
week for 4-5 h/day in an apartment with familiar furniture, objects and material (for details 
see Paper III).     
3 .3  Subjects and methods in Paper III      
Paper III described and evaluated a study, a new 12-month training programme, called the 
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Stimulation-Activation-Training (SAT) programme. It was developed within a dementia care 
nursing, to be a combined therapeutic treatment for patients with early-onset mild to moderate 
AD, and to be used when the patients underwent a drug treatment with intracerebroventricular 
infusion via an implanted infusion system.  
The study participants 
The patients were the same as in Paper II. They were 54-70 years of age, the duration of 
symptoms was 3 - 7 years and the MMSE scored 22 - 24. One Patient had rigidity subclonus 
and another Patient had gait disturbance with hypokinesia. They all had regional cerebral 
blood flow reduction, three Patients had brain atrophy, one Patient had widening of lateral 
ventricles, and one Patient had no abnormal findings in the imaging examinations. 
The patients, four women and one man, had been married for many years, and lived within a 
near area of the apartment in which the SAT programme was conducted. They started at 
different time of the four years ongoing study. 
Before participating in the study, all the patients and their spouses signed a consent form after 
detailed oral and written information about the treatment. The duration of the combined 
treatment was one year for each patient. The project was approved by the Ethics Committee, 
Faculty of Medicine, Göteborg University, and the Swedish Medical Products Agency. 
The therapeutic treatment 
The programme with timetabled cognitive, social and physical activities with stimulation, 
activation and training (SAT) procedures was used to treat patients with early onset, mild to 
moderate AD.  
A home visit was used before and about two weeks after the conduction of the neurosurgery 
due to the drug treatment, to supply information about real time home situation conditions. It 
was also used to give the participants a forward look at the timetabled training day for 4-5 
h/twice a week during one year. The start of the training programme with the five native-born 
Swede patients was set to about two weeks after the neurosurgery.  
The milieu and framework of the training programme 
A three room homelike, dynamic setting was used to attract the patients to encounter the 
training surroundings as recommend by Barris et al. [152]. One of the rooms was equipped as 
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a relaxing room and another as a working room to get privacy and autonomy as stated by 
Kahana [153]. A step by step demand was used to analysis the tasks/activity performance to 
correspondence to the patient’s real time performance capability [154].   
The theory. The focus of the activities in the SAT programme is based on a nursing theory 
[147] to assist and validate individuals and families to cope with and understand their 
experience of illness. Communication was used as a process to enable a human-to-human 
relationship. Continuously dialogue of the contents and results of the training was used to 
inform the patients and relatives.  
The aim. To optimise the patients’ best-preserved functions and abilities from their 
perspective, as regards their quality of everyday life, was the aim to be used in the SAT 
programme.   
The principal strategy: to get the patients to overcome disablement caused by impairment, 
activity limitations and participation restrictions, was used to plan and design individuality.  
The scheduled time for the patients’ performance of each activity, 30-60 minutes including 
breaks, was used to fit a patient group of mostly two patients and the instructor (a RN) and to 
avoid risk of cumulative stress. A limit of two cognitive activities that can succeed each other 
was used to give a balance between social and physical training.  
The procedures of Stimulation - Activation - Training 
For stimulation the verbal and non verbal communication was by the instructor used to: 
-  maintain the establishing reciprocal relationship during the treatment year; 
-  repeatedly encouraging patients including to try the use of aids/support; 
-  awaiting their spontaneous choices and own proposal; 
-  informing of or actively showing alternative ways of its performance; 
-  asking for patient’s opinions about how a given task should be performed. 
For activation all activities making patients actively and passively to take part in activities 
in a rational way was used to be an act towards achieving the purpose, held by the 
professional nurse practitioner instructor. 
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For training, related to AD, was used: 
-  cognitive support: given both when the patients took in what a certain task involve and 
   when they related their experience of the task;  
-  systematic training: a task was repeatedly performed in the same way and each operation              
   had to be completed before next one started; 
-  continuous plan of action with partial or final goals;  
-  tests of limitations of individual’s optimum capacity to perform and participate in various 
  activities while influenced by contextual factors; 
  within the process of learning. 
The cognitive, social, and physical training 
The same activity at the beginning and the same activity at end of the day were used to form a 
habit of recognition. The different activities and tasks in the SAT programme were interlaced 
to imitate real time performances at daily life at home.  
The cognitive training 
Systematic performance of exercises and strategies was used to overcome disablements and to 
reduce individual difficulties due to AD. Different tool and distinct feature was used as one of 
the key pathways to assist in developing independent functions. The patient’s intact motor 
skill was utilized to facilitate learning and handle functions of objects.   
The orientation sessions involved use of the patient’s intact motor skill, ability of visual 
perception of distinctive features, step by step task-demand analysis, and the instructor being 
at meeting place until the goal was reach. During all outdoor training, the instructor was in the 
view of the patients. 
The laying table exercises involved use of the patient’s spatial and stereognostic ability (the 
combined use of vision and perceiving and recognizing abilities).   
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A new tool, a computer with installed language exercises and a printer, was used: to teach the 
patients to use a new tool; to activate the patient’s ability to use required attention, 
concentration; to use their simultaneous capacity and procedural memory.  
Double support at the managing was used to start the teaching of the computer system step by 
step until the exercises were carried out by the patient’s themselves at their own path.  
The keyboard was used to writing exercises and the computer program was used to activate 
the patient’s vocabulary. The printer was used to print out their keyboard exercises of 
different individual decided productions.   
In language sessions, oral and writing expression was used to utilize the patient’s ability to 
express themselves.  Conversation practice was used to call attention to what had been said. 
Reading comprehension was facilitated by not asking details of the text. The patients’ 
semantic ability was activated by word-exercises, available both on paper and as computer 
exercises. Relating the content of read text was used to train working memory. 
Guidance in form of tear-off wall calendar was used to make the patients aware of time.  
The social training 
Conversation sessions with allotted time, was used to get the patients accustomed to 
participate, start and be active in exchanges of ideas. Allotted time was used to get each 
patient reasonable time to find words and to interpret what was said.  
The household activity was intended to teach the patients all the different tasks involved in a 
meal in daily life. Systematic training (see above) and step-by-step strategies as well as old 
habits were used to overcome activity limitations and participation restrictions due to AD. 
Dancing, singing, listen to music, watching TV or invite their families to coffee was used to 
making the patients happy in social togetherness within the quality of everyday life. 
Instruction was used to make the patient to decide themselves what kind of close social 
interaction they wanted.  
Visit to public places was used to a form of relaxation after two laborious cognitive activities. 
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The physical training     
Walks were regularly used in order to make daily exercise a habit and improve muscle-power 
functions. A cycle exercises was used as an alternative.  
Relaxation in form of muscle relaxation is used to reduce the patients’ basic tension.  
Instructions to be followed on a tape were used to provide five minutes progressive muscular 
relaxation with the instructor present at the beginning of the exercise.  
Tactile ball massage for three minutes was used to strengthen the signals of the patients’ 
sensory receptors and improve the patients’ ability to observe and be aware of their body. 
The relaxation activities were carried out only at a patient’s request during the treatment year. 
Table 2. Overview of the contents of the SAT program 
  Cognitive training 
          Memory 
learning of new material 
reporting 
time orientation 
Vision, sensation, perception 
orientation in the surroundings 
laying-table strategy 
reading strategy 
           Language 
usage (pragmatic) 
content (semantic) 
 Social training 
         Conversation 
experiences 
requests 
     Household activities 
shopping 
cooking 
          Social interaction 
dance music/singing  
visits to public places  
   Physical training 
         Motor function 
walks 
cycle exerciser  
          Relaxation 
rest 
relaxation exercise 
tactile ball massage 
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Assessment instruments 
The GBS scale, [46], was used to follow the functional state and symptom during each 
patient’s treatment year with 15 ratings. The rating was carried out before treatment, every 
second week for the first three months and then monthly during the treatment by the research 
nurse. The GBS scale has three subscales which measure intellectual impairments (GBS-I 
with 11 items), emotional impairment (GBS-E with 3 items), motor performance (GBS-M 
with 6 items), and the symptoms characteristic of dementia (GBS-S with 6 items) [47, 49].  
The BAS scale. The bodily symptoms of mental disorders were assessed about every third 
month on the Body Awareness Scale (BAS) by means of observations during movement tests, 
which consisted of 37 items [44]. BAS gives important information on the patient’s 
experience of his own body and observations concerning his body management and 
movement pattern. The evaluator had to be educated in the scale which is reliability and 
interrater reliability tested [44, 45]. The same physiotherapist carried out all the examinations. 
The Aphasia test, the NGA. The language development was observed about every third 
month by using the Swedish translation of Reinvang’s Norsk Grunntest for Aphasia 
(NGA)[43]. The Aphasia test is a rating of quality of spontaneous speech and comprehension, 
repetition, naming, reading, and writing. The Aphasia test is reliability and validity tested. 
The evaluator had to be educated in the scale [43]. The same speech therapist carried out the 
examinations.
The Activity scale. All forms of activities were documented in four steps from score 0 
“independent performance” to score 4 “not being able to perform the activity”. The scale was 
developed for our studies of AD in Study I, II, III, and V in this thesis [unpublished].  
Daily Notes. All documentation was recorded by the research nurse to verify continuous 
various outcomes and nursing care, during the treatment year of each patient.    
3 .4  Subjects and methods in Paper IV 
In Paper IV an evaluation form, the Clinical Global Impression, was given to five spouses to 
patients with early onset mild to moderate AD.  On the CGI form an extra space was made for 
voluntary comments, which constitute the date in this study. 
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The participants 
The spouses were gathered from Study II in which they had been judged willing to and 
capable of evaluating the effect of the treatment. In that study their husband/wife underwent a 
one year drug treatment combined with a SAT programme performed 4-5/h, twice a week in a 
training apartment. The spouses started their one year participating at different time of the 
four ongoing years.  
The evaluation form 
The professional person (a RN) at the training apartment monthly handed the CGI form over 
to the spouses, who, after filling in the form at home, returned it to the nurse in the training 
apartment. The instructions to the spouses were that the filling in comments was voluntary 
and also on the form:”The evaluation is valid from the preceding evaluation until today”.  
A total of 60 evaluation forms (12 forms/per spouse) with extra space for voluntary comments 
was collected from the five spouses. Seven forms contained no comments. Thus the data 
consisted of 53 different forms with comments from five spouses. It is the 277 comments on 
the 53 different forms that constituted the data in this study. 
The analysis   
The comments were analysed by means of content analysis [168, 169]. The analysis of the 
content of the comments was performed in four steps.
In the first step, the comments were read and reread several times to obtain an overall picture 
of the written material. Words, statements, and events, dealing with the related content were 
grouped into themes, temporarily named according to the content. The analysis continued 
with reflections on words, statements and events of belonging in existing themes and 
relevance to the purpose of the study. Any additional units were added to the different themes 
or, if necessary, further themes formed.  
The second step was to establish the themes. Eight preliminary themes emerged from the data 
and after an inventory a total of four themes were finally established. These themes were 
named according to their content. It was found that certain areas had more in common with 
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each other. These areas were called sub themes and were assigned headings based on their 
content.  
In the third step, the analysis was supplemented by a frequency pattern. The frequency of 
each theme, and each subtheme, was marked for each participant and the sums of the theme 
groupings were added together to form a total for the whole year. 
 The fourth step, the interrater reliability was estimated by means of an independent co-
examiner [169]. After the independent operation, the examiner and the co-examiner arrived at 
a consensus as regards the main themes and subthemes by discussing and reflecting on the 
research question.    
3 .5  Subjects and methods in Paper V     
In Paper V the Norwegian Basic Aphasia Assessment “Norsk Grunntest for Afasi “ (NGA) 
was used to examine linguistic development of patients with AD at baseline and over time. 
This was done when they, during systematically performances of language activities 
participating one year in a stimulation-activation-training (SAT) programme. The SAT was a 
therapeutic treatment which was combined to an intracerebroventricular treatment with GM1. 
The patients      
The patients had early onset form of AD [16, 34], they were 54-69 (m=64) years of age, mild 
to moderate dementia with intellectual impairment specified as maximum score of 4 on the 
GBS scale, and a score of 22-24 out of 30 on the MMSE [42, 46]. Education years were 7-10 
and two patients had supplementary education. The patients were native Swedish-speaking 
people, lived at home with a Swedish spouse and started their participating at different time of 
the four ongoing years of the SAT.  
Before participating in the SAT programme study (Paper III), all the patients and their 
spouses signed a consent form after obtaining detailed oral and written information about the 
treatment.  
The setting and the training     
The performances took place in a rented apartment. It had a kitchen, a dayroom, a relax room 
and a workroom, all looking homelike. The training was carried out by two patients and the 
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instructor (a RN) for 4-5 hours, twice a week during 12 months for each patient. Each activity, 
including a break, was scheduled to take 30-60 minutes. The aim of SAT is to optimize the 
functions and abilities that are important in patients’ everyday life [79].   
The lots of language performances were parts of the everyday activities in the SAT 
programme. This comprised language sessions in the cognitive training (which also had 
memory- and orientation sessions); included regularly held conversation sessions in the social 
training (which also had housekeeping and social interaction); and the SAT programme 
encompassed physical training with motor function and relaxation sessions.  
The cognitive activities that could succeed each other were limit to two, to balance the 
cognitive and physical training. 
The language activities in the cognitive training 
The language activities were used to deal with the usage (pragmatic understanding) and 
content (semantic understanding) of words and phrases in reading and writing session. To 
carry out these language activities a personal computer system (new tools for all patients) e.g. 
a computer, a keyboard, a mouse and a printer was used. Selected mixed 37 exercises, 
installed and displayed one at a time on the computer screen, was used to activate the patient’s 
vocabulary, which might make them recall previously acquired knowledge of words, the 
content - semantic ability. The results chart in the computer and same instructions for each 
exercise was used to standardize the test situation. The short program exercises were used to 
match the exercises described on paper.   
To activate the patients’ vocabulary; word comprehension; and understanding of the content 
of the texts, there were use of paper which had objects and text with one or more questions on 
the same paper. The answer was given orally or written by hand.  
A reading strategy in form of an eye-moving technique was used for patients who had eye 
problem when following lines in the text e.g. in news paper.    
In writing sessions, the keyboard, pen or pencil was used. Keyboard productions were 
message to someone; timetables of the examinations, various personal notes e.g. telephone 
numbers with big digits, letters and English words, and family agendas. Support in spelling 
and word finding was provided by the instructor.  Handwriting was used to put their names on 
sheets, to note down their performances during the day in their pocket diaries, and to enter 
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personal memos in their binders. The instructor supported, if necessary, the patients in 
spelling and word finding.  
The language activities in the social training 
Regularly held conversation sessions to utilize each patient’s own vocabulary and counting 
(mostly used at shopping for lunch in housekeeping) were used to take part in social training.  
The conversation sessions were regularly held to form a routine, habit. The sessions were held 
for 30 up to 60 minutes at start and for a maximum 30 minutes at the end of the day and both 
the patients and the instructor participated. The subjects of conversation was decided by the 
patients e.g. own experiences, their proposal of lunch or requests of specific exercise or task 
to utilize each patient’s own vocabulary. Allotted time for all participants was used to give the 
patients time to find words, to focus on what are said and not who said it.   
Common general-knowledge words in everyday talk were used to making creative use of: 
what was left of their previously acquired richness of vocabulary; their knowledge or feelings 
of knowledge of a topic; and their existing semantic lexicon.  
The talking about the same subject of all three participants was used to avoid 
misunderstanding, which must be semantically relevant. That is because of the connection 
between question and answer. 
Support in word finding, if necessary, was used by the instructor to keep the informativeness 
high and included the use of eye contact with the patients. 
The assessment of the linguistic development 
The NGA assessment is a Norwegian standardized test, based on patients with aphasia, for 
measuring degree and type of aphasic impairment. The test measures fluency, comprehension, 
repetition, naming, reading and writing. The sum of the total score of the main variables 
yields the aphasia coefficient, which is a measure of the severity of language impairment. 
NGA was supplemented with a selected narrative with a good point (length 89 words). 
A detailed description of NGA, including its rational, reliability, validity and origins is given 
by Reinvang [43]. The same speech language pathologist, educated in NGA assessment, 
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carried out all the assessments at her office. The patients were generally examined on five 
occasions. The NGA is general used by speech language pathologist [170].    
In the present study, the pre-test (at start) and post-test (at 12 months) results was shown.   
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4   ETHICAL CONSIDERATIONS   
Research on persons with diminished judgement ability is ethical problematic and therefore it 
can be argued that studies should not be made on persons with dementia. However, if 
dementia is excluded from medical studies, no progress in the treatment could be made. 
Ethical analyses and ethical restriction have been discussed on this issue [171, 172]. 
Following the recommendations of the World Medical Association Declaration of Helsinki 
[173] all patients signed a consent form after detailed oral and written information before 
participating in the treatment project. They were also informed that they could interrupt the 
treatment at any stage. The relatives received the information together with the patient, and 
were also asked to give their written consent. 
In addition the degree of dementia according to the GBS scale was to be scored at most 4 on 
items measuring intellectual impairment, to make it possible for the patients to understand and 
to give a well-based consent to the study. 
 In Study III, the caregivers got supplied information of the stimulation-activation-training 
(SAT) programme information, to help them understand the strategy of the treatment. Further, 
the content and result of the training were continuously discussed with the patients and 
relatives, either individually or together at the beginning or end of the day.  
In Study IV the spouses are named spouse 1 to 5 to ensure confidentiality and in Study V all 
the patients are referred to as “she”, to give anonymity. 
The study was approved by the Ethics Committee, Faculty of Medicine, University of 
Gothenburg, and the Swedish Medical Products Agency. 
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5   RESULTS 
5 .1 Paper I 
In Paper I, the first study, it was evident that there was a need of complex and extensive 
following ups during the treatment year. There was especially a need to determine the 
therapeutic dose of GM1, as it was hitherto unknown, and also to follow the performance of 
the combined home based activation.   
The ganglioside dose 
The start dose of GM1 during the first three months was 30mg/24 h according to Patient 1. 
This dose was reduced to 10mg/24 h, however, it was evident that the patient´s function 
deteriorated. The dose was then changed to 50mg/24h to compensate the low dose. After a 
few days the Patient 1 developed symptoms of delirium with signs of disorientation and 
headache. The dose was then reduced to 20 mg/24h and the symptoms of delirium vanished. 
For Patient 1, a dose of 20 mg GM1/24 therefore appeared optimal. 
All four of the subsequent Patients (Patient 2 - Patient 5) received an initial dose of 30 mg 
GM1/24 h. The dose was reduced to 20 mg/24h, if they showed signs of delirium.  
The pre-treatment level of GM1 in lumbar CSF was 11 – 45 nmol/l and in the brain 
ventricular CSF 10-26 nmol/l.  
The steady-state level of GM1 on daily dose of 30 mg/24h was 40-50   mol/l, on daily dose 
on 20 mg/24 h was 18-22  mol/l; on daily dose on 10 mg/24 h was 5-8  mol/l.  
This means that in lumbar CSF the GM1 concentration rose approximately 1,000 times when 
the patient received 30 mg GM1/24h.        
Adverse events 
The following major adverse events occurred:   
Patient 2 showed after three months a sign of mild meningitis, which ceased without any 
treatment. On day 250, the Patient fell and the head was hit. The break in the connection 
between catheters and pump was not detected until 40 days later.  
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Patient 3 did not receive adequate GM1 therapy during the first 5 months due to three adverse 
advents. A break of the connections between catheters and pump was diagnosed on day 30, a 
subdural hematoma diagnosed on day 47 and evacuated, and a new break was diagnosed on 
day 90. This had probably  occurred a month earlier.  It was not possible to reconnect the 
catheters with the pump until day 152.           
Patient 5 had postoperative CSF leakage, which caused moderate pneumocephalus leading to 
extra-cerebral effusion. This had to be removed via a burrhole and drainage. On day 80, at a 
routine CT control, bilateral subdural hematoma was found and subsequently evacuated. 
The analyses of brain scan and laboratory examinations  
The blood flow were analysed with rCBF examinations. These showed at start significantly 
lower rCBF in the temporoparietal regions in comparison to age matched controls. Further 
significant reductions were found in the hippocampal, lateral temporal and basal frontal gray 
matter regions, in comparison to the control persons. No significant changes were seen in the 
rCBF during the treatment period.  
The initial low values for HVA increased significantly in all patients between days 0 and 360, 
except for Patient 1.  Somatostatin increased, especially in Patients 3 and 4.  
The analysis of blood chemistry, haematology and urine analysis showed no abnormality at 
measured during the one year. Two of the patients had slightly increased CSF/serum albumin 
ratios before treatment, which remained elevated during the whole treatment period. None of 
the patients had increased antiglycolipid IgG or IgM antibody titers before the treatment. The 
titers remained low for all antigens tested during the whole treatment period. 
Neuropsychological examinations 
The neuropsychological assessments (Fuld sum 5 trials, Digit Span, Similarities and 
Face identity) are summarized in a total score as the patients’ cognitive ability. The 
assessment of Patient 1, 2 and 4 showed a score indicating improvement of the assessed items 
on day 90 as compared with the measurement before treatment.  
On Patient 1 and Patient 2, the sum of the cognitive scores was increased on day 360 
compared with the measurement before treatment, indicating improved ability, ADAS and 
GBS showed a similar picture.  
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Patient 4 performances of tests of cognitive ability and of MMSE are missing on day 360. 
The level in MMSE showed no increasing values of the five patients at Day 360. 
The GBS ratings of intellectual functions for Patient 1 showed continuous decreased score, 
indicating improvement of the rated items during the whole study period. Assessment scores 
of Patient 2 and Patient 4 indicate some improve of these performances between days 30 and 
360. Patient 3 did not show any change. Patient 5 scores indicated a decline on day 360.  
The home based activation 
The documentation by the spouses of their partner’s performed activities showed less 
frequently occasions at the end of the year compared at the start of the study. The 
documentation in the Daily Notes, by the research assistant, showed increase of amount of 
supply directed to activate the patients as requested by the spouses and the patients. The 
general impression of the relatives, according to the Daily Notes, was that all 5 Patients 
showed some improvement. Three of the patients gained weight, while the remaining two 
showed unchanged weight. 
5 .2 Paper II 
In the ganglioside GM1 treatment study all patients received an initial dose of 30 mg of 
GM1/24 h. This dose was based on the preliminary data from the first study (Paper I) of the 
patients’ reaction on the doses given.   
The ganglioside doses 
Before treatment in the study, the level of GM1 in ventricular CSF and lumbar CSF in this 
study was varied from 16 to 32 nmol/l. 
Treatment with 30mg of GM1/24h increased the concentration about 2,000 times in lumbar 
CSF. The steady-state level of GM1 on this dose varied between 40,000 (means 40 µmole) 
and 60,000 nmol/l (means 60 µmole).  
The concentrations of the other major gangliosides, GD1a and GD1b, did not change 
significantly during the treatment, thus they were not influenced by the increased level of 
GM1.  Patient 1 had a dose of 30 mg; between days 165 – 210 there was an interruption of the 
treatment. 
Ingalill Ramström
52
Patient 4 performances of tests of cognitive ability and of MMSE are missing on day 360.
The level in MMSE showed no increasing values of the five patients at Day 360. 
The GBS ratings of intellectual functions for Patient 1 showed continuous decreased score, 
indicating improvement of the rated items during the whole study period. Assessment scores 
of Patient 2 and Patient 4 indicate some improve of these performances between days 30 and 
360. Patient 3 did not show any change. Patient 5 scores indicated a decline on day 360. 
The home based activation
The documentation by the spouses of their partner’s performed activities showed less 
frequently occasions at the end of the year compared at the start of the study. The
documentation in the Daily Notes, by the research assistant, showed increase of amount of 
supply directed to activate the patients as requested by the spouses and the patients. The 
general impression of the relatives, according to the Daily Notes, was that all 5 Patients 
showed some improvement. Three of the patients gained weight, while the remaining two 
showed unchanged weight.
5 .2 Paper II
In the ganglioside GM1 treatment study all patients received an initial dose of 30 mg of
GM1/24 h. This dose was based on the preliminary data from the first study (Paper I) of the
patients’ reaction on the doses given.  
The ganglioside doses
Before treatment in the study, the level of GM1 in ventricular CSF and lumbar CSF in this 
study was varied from 16 to 32 nmol/l. 
Treatment with 30mg of GM1/24h increased the concentration about 2,000 times in lumbar 
CSF. The steady-state level of GM1 on this dose varied between 40,000 (means 40 µmole) 
and 60,000 nmol/l (means 60 µmole). 
The concentrations of the other major gangliosides, GD1a and GD1b, did not change
significantly during the treatment, thus they were not influenced by the increased level of
GM1.  Patient 1 had a dose of 30 mg; between days 165 – 210 there was an interruption of the 
treatment.
53 
Patient 2 showed a slight overactivity after only 2 months of treatment. The CSF GM1 level 
was over 50,000nmol/l. As this Patient had mild depression at entered the study, this 
overactivity was regarded as positive, and the dose was not lowered to dose 20mg/24h until 
the Patient showed signs of delirium on Day 240.  
Patient 3 had a dose of 30 mg/day. 
Patient 4 had a CSF GM1 level of over 57,000 nmol/l by Day 30, and when signs of delirium 
was shown by Day 50, the dose were lowered to 20 mg/24 h. The power of initiative based on 
the spouses observations, gradually diminished why the dose was increased to 25mg/24 h. 
Patient 5 had a dose of 30 mg/day. 
In this study the GM1 doses variations were: from 30 mg-25-20 mg/24h, which showed a 
marked narrow therapeutic interval. 
The pump was not functioning properly for about 50 days in Patient 1, and the estimation 
showed that the patient did not receive any GM1 from Day 165 to Day 210. During this 
period GM1 level dropped from 40,000 to 280 nmol/l, which indicates an interruption in the 
GM1 treatment.  
The change of CSF transmitter metabolites 
The CSF sample, which was taken about 25 days after the pump of Patient 1was not working, 
showed decreased HVA levels and even more marked decrease in the CSF somatostatin 
concentration. These levels increased when GM1 was re-administrated. This gave ability to 
evaluate the effect of SAT training without GM1 treatment, which suggests an effect of the 
GM1 treatment on the concentrations of CSF HVA and somatostatin. 
 HVA: The CSF concentration of HVA, the major metabolite of dopamine, was within the 
normal ranges for healthy persons at start in Patient 1. Values for HVA increased significantly 
during treatment in Patients 1, 2, 3 and 5 by day 90. The effect of GM1 on dopamine thus 
remained during the study. 5-HIAA:The initial CSF concentrations of 5-HIAA, the major 
metabolite of serotonin, values were low in patients 3, 4 and 5, compared with the normal 
ranges for healthy persons, and increased  during treatment in all patients except Patient 4. 
HMPG: The CSF concentration of the noradrenaline metabolite HMPG was within the 
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normal ranges for healthy persons and did not change with treatment. Somatostatin levels 
were low in all patients before treatment but increased rapidly after start of the treatment. 
Analyses of brain scan and laboratory examinations  
The 5 patients had significantly lower rCBF in the basal frontal, frontal association and 
temporoparietal regions  as well as white matter parietal and semi-ovale center regions 
(p<0.01), indicating reduced blood flow in these areas. Less significant reduction were 
recorded in the hippocampus, mesencephalon, gyrus singuli, motor cortex, parietal association 
cortex and frontal white matter (p<0.05). Although the relative blood flow was higher in 
many regions in four of the five patients after treatment for 1 year, the changes were not 
significant. 
No abnormality was noted in blood chemistry, haematology or urine analysis measured every 
3 months. Lumbar CSF cytology, CSF albumin, IgG, and IgM were normal in all samples. 
Samples of lumbar CSF were taken every 3rd month, except for Patient 3, why these 
measuring results are missing on Day 180 and Day 270. In serum, none of the patients had 
increased anti-GM1 or anti-GM1 epitope carrying IgG or IgM reactivity. Bacterial culture and 
endotoxin determinations of the pump content at each refilling were negative.  
Clinical symptoms of the patients 
None of the patients showed symptoms of emotional disturbance, psychosis or paranoia. The 
treatment of Patient 3 with citaloprame (Cipramil®) was continued as before the entry of the 
study. She showed no symptoms of depression during the study period.  
Patient 1 and Patient 4 had mild extrapyramidal symptoms at start of the study which 
disappeared within the first month.  
Neuropsychological examinations 
The majority of items in the five patients showed no certain trend. In these items all five 
patients showed: 
- improvement of intellectual functions, according to the GBS scale 
- improvement of assessment of prosopagnosia (face identity).      
- unchanged score of tactile agnosia (according to Fuld’s object memory test). 
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- kept the same score at assessment of emotional lability, emotional function and of stress   
  tolerance according to the GBS scale, during the treatment year.     
Table 3. Function and/or symptom and neuropsychological tests of 5 Alzheimer patients 
  Patient 1    Patient 2    Patient 3    Patient 4    Patient 5 
  0    365    0   365    0    365    0    365    0    365 
Short-term memory impairment  
(recent memory, item I 4, G scale)    4    3 (+)    4    4 (u)    4   3 (+)    2      2 (u)    3      3(u) 
Long-term memory impairment
Long-term memory impairment 
(distant memory, item I 5, G scale)    4    2 (+)    2     2 (u)    1     2 (–)    2       2 (u)    2      2 (u) 
Personality change 
Emotional function, item E 1, G scale    1    0 (+)    0    0 (u)    0    0 (u)    0      0 (u)    1      0 (+) 
Emotional lability, item E 2, G scale      0       0 (u)    0    0 (u)    0    0 (u)    0      0 (u)    0      0 (u) 
Emotional function, item E 3, G scale    0    0 (u)    0    0 (u)    0    0 (u)    0      0 (u)    0      0 (u) 
Stress tolerance 
(inability to increase tempo, item I 8, G scale)      2       2 (u)    2    2 (u)    3   1 (+)    3      2 (+)    2      2 (u) 
Disturbance of consciousness 
(confusion + clinical observation)    1      0 (+)    1     1 (u)    1      1 (u)    1      1 (u)    0      1 (–) 
Abstract thinking (similarities)         10     20 (+)    2     6 (+)    8       8 (u)    19    20 (+)    9    12 (+) 
Dyscalculia (arithmetic test)    10       8 (–)    8    10 (+)    9       5 (–)    8     7 (–)    5      4 (–) 
Sensoric aphasia (ADAS, item 10)    0       0 (u)    0      1 (–)    0       0 (+)    0     0 (u)    0      0 (u) 
Episodic memory  
(Fuld’s object mem test, tot numb recall, 5 trials)18    23 (+)    18    20 (+)       13     13 (+)    26     35 (+)    22    20 (–) 
Attention (Trailmaking test – part A)    62 s  53 s(+)     39 s  65 s(–)     65 s   95 s(–)    n.t.  305 s(+)     45 s  48 s(–) 
Capacity of simultaneous thinking 
(Trailmaking test – part B)         210  235 s(–)     n.t.    n.t.    n.t.       n.t.    n.t.      n.t.    n.t.       n.t. 
Motor aphasia (ADAS, item 9)    1    0(+)    1      1 (u)    2       3(–)    1    1(u)    0    1(–) 
Tactile agnosia 
(Fuld’s object memory test)       10    10 (u)       10   10 (u)    10    10 (u)    10     10 (u)    10     10 (u) 
Prosopagnosia (face identity)    44      57(+)      30   33 (+)    34    35 (+)    31     48 (+)    44    54 (+) 
Visuospatial inability 
(Koh’s block test)    3     12 (+)       7      8 (+)    0      0 (u)    0       0 (u)    9       6 (–) 
Executive functions (ADAS)    0       0 (u)    0      0 (u)    2      3 (–)    2       3 (–)    2      0 (+) 
MMSE    22     27 (+)     24     24 (u)       23    18 (–)    23     23 (u)    24    24 (u) 
Intellectual functions (G scale)    17    10 (+)     14     13 (+)       19     11 (+)    15    9 (+)    17      9 (+) 
Similarities, dyscalculia, Fuld’s tests and MMSE [7]: increasing values = improvement (+); (ADAS) [7] and G scale [10]: 
increasing values = impairment (–);  u = unchanged;  n.t. = not testable;  I = intellectual scale;  E = emotional scale.
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5 .3  Paper III 
The implementation of the content of the SAT program was unquestionably gradually in real 
time of all performances and caring out with active participating of the patients as shown in 
the results.  No drops out, no sign of cumulative stress was in the results, all tools was used 
within the SAT programme, and performance goal of all activities during the one year 
treatment were reaching. 
The results on the Activity scale, developed for the combined treatment of patients with early 
onset AD, showed that all the patients, after a maximum of nine months, had learned to 
perform a series of all tasks associated with a complex household activity. These comprised 
eleven tasks from planning a meal to put item back where they belong. These tasks are e.g. 
plan the meal, write a shopping-list, all tasks involved in shopping, finding the way to and 
from the shop, cooking, laying the table, and to wash up and put the back the items to their 
belonging.  
The Patients active participating 
Making favourite choice: 
- four of the five patients chosen singing rather than dancing of the activities in 
interaction. One patient did not choose either of these activities. 
- all five patients within the free choice activities chose computer programs and writing on 
   the keyboard. 
- resting in bed was the most common choice of the relaxation activity.   
This active participating showed that all patients had learnt to use new tools, a computer with 
a keyboard, and a printer. 
It was also shown that all patients learnt to use a computer programme with its different 
exercises. Further, the computer chart showed that all five patients did not choose six of the 
computer exercises which content had maths involvement.        
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Making requesting preference: 
- the activity with instructions for progressive muscular relaxation was more frequently  
  requested than tactile ball massage, seen as a group result. 
An astonishing outcome was that the patient with severe visuospatial impairment, without 
assistance, extended his learning by finding the way to the bus stop and going by bus to and 
from home. The results of that the Patients brought with them material to copy on the 
computer for printing, CDs and a video cassette containing an amusing film, was an extension 
of choice to be used within the social relaxing activities. 
The examinations with standardized instruments 
The results based on examinations with standardized instruments unveil that all patients had 
shown features of increased maturity. This is based on to the speech therapist’s examinations 
of linguistic performance by the NGA test and the physiotherapist’s examinations of the 
patients’ body management and movement pattern by the BAS scale.  
Table 4. The change in values as assessed on GBS scale, BAS scale and in Aphasia test 
  Patient    Patient    Patient    Patient   Patient 
 ________________________________1_______    2__________3_________4__________5________ 
The GBS scale        
Intellectual impairment: 11 items 
Max impairment score: 66       
Baseline/6 months/12 months  17/11/10      14/14/13       19/14/11       15/11/9   17/12/ 9 
The BAS scale 
Observations of symptom: 37 
Number observations:        
Baseline/6 months/12 months   14/-/11  10/5/5  16/10/13       12/13/15  8/ 7/ 5 
The Aphasia test 
Auditory comprehension 
Subtest: 8         Max score:71  
Baseline/6 months/12 months   71/-/71       70/71/71       69/69/69      71/71/71   70/71/71 
_____________________________________________________________________________________ 
GBS scale and BAS scale: decreasing score = improvement   Aphasia test: increasing score= improvement  Errata in the original 
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However, some items did not show clear-cut results. The items in which they all patients 
reduced their scores of disabilities or kept the same score from the first rate at the last 
measurement became prominent. This outcome may indicate an improvement which was 
shown in movement function and movement behaviour assessed by the BAS scale and in 
auditory comprehension in the NGA test.  
The rating with the GBS scale of the 11 items of intellectual impairment showed increased 
orientation ability in the items space (I:1) and in time (I:2) for all the patients as indicated in 
accordance  of the scale. The GBS scale measured dementia symptoms and decreased score 
indicated that the Patients improve or had the same ability to perform the item in question, 
during the treatment year.   
5 .4 Paper IV     
Paper IV shows the analysis of spouses’ depicted 277 voluntary comments from 53 forms 
monthly filled in a form during one year.  
Seven forms, mostly from the first six months, contained no comments due to the spouses 
claiming difficulty to make comments.  
These voluntary comments were their views of the content of their jointly life at home and 
their focus when they made judgments.  
These comments are collected in four themes with subgroups, respectively. 
The results of the analysis are presented as an overview of frequencies and percentage of the 
four themes and subthemes and are shown in Table 5.  
Ingalill Ramström
58
However, some items did not show clear-cut results. The items in which they all patients 
reduced their scores of disabilities or kept the same score from the first rate at the last 
measurement became prominent. This outcome may indicate an improvement which was 
shown in movement function and movement behaviour assessed by the BAS scale and in 
auditory comprehension in the NGA test. 
The rating with the GBS scale of the 11 items of intellectual impairment showed increased 
orientation ability in the items space (I:1) and in time (I:2) for all the patients as indicated in 
accordance  of the scale. The GBS scale measured dementia symptoms and decreased score
indicated that the Patients improve or had the same ability to perform the item in question, 
during the treatment year.  
5 .4 Paper IV
Paper IV shows the analysis of spouses’ depicted 277 voluntary comments from 53 forms
monthly filled in a form during one year. 
Seven forms, mostly from the first six months, contained no comments due to the spouses 
claiming difficulty to make comments. 
These voluntary comments were their views of the content of their jointly life at home and 
their focus when they made judgments. 
These comments are collected in four themes with subgroups, respectively. 
The results of the analysis are presented as an overview of frequencies and percentage of the
four themes and subthemes and are shown in Table 5. 
59 
Table 5. Overview of frequencies and percentage of themes and subthemes 
The spouses’ view  
Theme and Subtheme 
Sum of the 
frequency 
and  (%)  
of all 
comments of 
the  spouses 
 Frequency and (%) of each theme and subtheme of  
the five spouse’s comments and the total  sum        
Spouse 1 
Male  
Years of 
Age 68 
Spouse 2 
Male 
Years of 
age 68 
Spouse 3 
Male 
Years of 
age 67  
Spouse 4 
Female 
Years of 
age 62 
 Spouse 5 
Male  
 Years of 
 age 56  
TOTAL a round sum of percentage   (100%) 
1. Spouse’s view of the partner’s activity. 106   (38%) 31 (39) 17 (34) 12 (48) 35 (40%) 11 (32%) 
activity level 7 9 6 6 5 
Housework 17 5  4 23 0 
social activities 1 1 2 5 6 
selected activities 6 2 0 1 0 
2. Spouse’s view of the partner’s general
health conditions and capabilities. 
83  (30%)  25 (31%)  20 (40%) 4 (12%) 22 (25%) 12 (35%)  
health, stress, mood 3, 1, 6 4, 1, 3 0, 0,1, 6, 4, 6 2, 0, 0 
self-confidence, awareness 1, 0 1,1 1, 1 0, 1 4, 4 
Orientation 3 3 0 4 1 
memory function 11 7 1 1 1 
3. Spouse’s view of influence of the
environment. 
15  ( 5%)  3 (4%) 1 (2%) 1 (4%) 10 (11%) 0 (0%) 
close relatives/friends’ opinions 1 1 0 0 0 
partner’s experiences 2 0 1 10 0 
4. Spouses’ view of their own  responses in 
relation to the partner. 
73 (26%)  21 (26%) 12 (24%)  8 (36%) 21 (24%) 11 (32%) 
at home, at work, to own health 5, 1, 1 0, 0, 0 1, 0, 0 5, 0, 1 4, 0, 0 
 behaviour with an obvious cause  3 3 2 4 2 
 emotional behaviour  3 0 5 10 3 
 behaviour relating to forgetfulness  8 9 0 1 2 
SUM of frequency of each spouse 80 50 25 88 34 
Number of CGI form with comments 
/ total number   11  /  12   12  /  12   7  /  12  11  /  12 12  /  12  
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The original important comments from each theme are illustrated, collected from the spouses 
comments. 
Overview of the original important comments 
Spouse’s view of the partner’s activity showed the highest sum and frequency of the four 
themes. This theme has four subgroup and the dominating comments showed that all the 
Spouses focused mainly on activities and on activity levels performed in their daily life at 
home. They judged their partner’s performance skills without commenting on demands for 
support or help from the partner.  
The theme Spouse’s view of the partner’s general health conditions and capabilities has 
four subgroups. All Spouses judged the memory function in terms of “recent and /or distant 
memory”, especially of patient 1 and patient 2. 
The theme Spouses’ view of their own responses in relation to the partner has four 
subgroups. In the subgroup behaviour with obvious cause showed that all spouses found these 
in related episodes, in which their partner’s manners had an understandable cause.  
The comments in the subgroup behaviour relating to forgetfulness were often referred to 
episodes as absent-mindedness and a problem with agreements, especially of Spouse 1 and 
Spouse 2.  
Less frequency and sum was shown in the theme Spouse’s view of influence of the 
environment which has two subgroups. The person mentioned was a daughter and good 
friends. In subgroup partner’s experiences the comments by the Spouse 4 consisted more of 
utterances of negative feelings mostly that: “he thinks he can’t manage things and I have so 
much to do” than positive.     
5 .5  Paper V  
In Paper V, the patients’ linguistic development based on 12 months language training is 
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made by scoring of a standardized test, the NGA. It is also complemented by other assessment 
which including speech quality. 
The results of the NGA assessments made by scoring are presented in Table 6. 
Table 6. Degree of language functioning in five patients with mild or moderate AD at start of the study 
and at 12 months. The scores are the numbers of correct answers to set questions.  
Variables Subvariables 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Start/12m Start/12m Start/12m Start/12m Start/12m 
Auditory 
Compre-
hension 
Body parts, identify (0-  11)   11  /  11  11  /  11  11  /  11  11  /  11  10  /  11 
Body actions (0-10)  10  /  10   9  /  10  10  /  10  10  /  10  10  /  10 
Objects, actions (0-10)  10  /  10  10  /  10   9  /  9  10  /  10  10  /  10 
Ideas, meaning (0-14)  14  /  14  14  /  14  13  /  13  14  /  14  14  /  14 
Total               (max 71)  71  /  71  70  /  71  69  /  69  71  /  71  70  /  71 
Repetition Words (0-20)  20  /  20  20  /  20  20  /  19  20  /  20  20  /  20 
Sentences (0-12)  11  /  11  11  /  11  11  /  10  12  /  12  11  /  11 
Total    (max 40)  39  /  39  39  /  39  39  /  37  40  /  40  39  /  39 
Body actions (0-5)   5  /  5   5  /  5   4  /  5   5  /  5   5  /  5  
Objects action (0-5)   5  /  5   5  /  5   5  /  4   5  /  5   5  /  5  
Responsive (0-10)  10  /  10  10  /  10  10  /  10  10  /  10   9  /  10 
Total    (max 41)  41  /  41  41  /  41  40  /  39  41  /  41  40  /  41 
Syntax Sentence arr  (max 6)   6  /  6   6  /  5   6  /  6   6  /  6   4  /  6 
Writing 
Aphasia 
coefficient  
Total    (max 10) 
(Total)    (max 217) 
 10  /  10 
216 / 216 
 10  /  10 
215 / 215 
  9  /  9 
212 / 209 
  7  /  4 
214 / 211 
 10  /  10 
212 / 216 
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The degree of language functioning in each patient is summarized as follows: 
-  All five patients showed during the whole assessment period maximum scores on reading 
   comprehension and maximum scores on reading aloud.  
-  Patient 1 and Patient 2 had an aphasia coefficient (total sum score) that did not change 
    from the start to the end of the study.  
-   Patient 3 showed a decline in scores on repetition and naming but kept the other variable 
    scores for the whole period.  
-   Patient 4 showed decline in writing but kept maximum score on all the other variables 
    during the whole period.  
-   Patient 5 had a 4-score improvement 
The five Patients reached a maximum score on reading comprehension and on reading aloud 
from the start to the end of the treatment year.  
To established possible changes, an analysis of their performance is needed. 
Detailed examination of each patient’s performance by the speech pathologist is shown 
below. 
Original excerpts of language functioning 
Patient 1, at 12 months. (Conclusion): Her linguistic competence has not become 
impaired during the last year. If anything, greater certainty is observed in her management of 
the language. She has improved her reading comprehension of visually presented text.          
However, her difficulty with retrieval of auditorily presented unrelated words, i.e. her 
memory reduction, remains. She has pronounced dyscalculia. At the start, the fluency of her 
spontaneous speech was 117 words per minute and the mean length of her utterances was 7.3 
words. 
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Patient 2, at 12 months. In the introductory conversation, she talks adequate about her 
own problems. Conclusion: Her greatest linguistic problems are secondary to her reduced 
memory capacity. At the start, the fluency of her spontaneous speech was 160 per minute and 
the mean length of her utterances was 6.4 words. 
Patient 3, at 12 months. The most prominent features in her spontaneous speech are 
hesitations and pauses when she describes a course of event. There is latency in her 
confrontation naming of content, but she can sometimes be helped by prompting. Her reading 
speed of a connected text is 89 words per minute, which is slow. She has dyscalculia. At the 
start, the fluency of her spontaneous speech was 64 words per minute and the mean length of 
her utterances was 4.0 words. 
Patient 4, at 12 months. Her reading speed is 70 words per minute (by Swedish 
standards, the measures range between 121–221 words per minute). Her writing ability is 
worse; she has more spelling errors: four of 10 words correct, the most pronounced errors 
being reduplications such as ‘clocck’. She has problems with arithmetical tasks. Conclusion: 
The patient has good linguistic competence, with exception for her reading ability, which is 
impaired primarily because of reduced memory function but also because of eye problems. 
Her capacity fluctuates. At the start, the fluency of her spontaneous speech was 95 words per 
minute and the mean length of her utterances was 5.9 words. 
Patient 5, at 12 months.  Sometimes she makes a break for word searching, but this 
hardly disturbs the communication. A few misspellings occur, but her sentence construction is 
good. She suffers from dyscalculia including both digit calculation and other mathematical 
operations. Her linguistic test profile has been solid without decline during the year. At the 
start, the fluency of her spontaneous speech was 112 words per minute and the mean length of 
her utterances was 7.3 words.   
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6  DISCUSSION    
A cure for AD is unfortunately still a mirage bearing in mind the ongoing increase of amount 
of people getting AD diagnosis. On the way towards the final goal, all possible reliable 
pharmacological agents and therapeutic interventions with reasonable treatment technique is 
crucial, especially since early intervention is important. This thesis will deal with one attempt 
towards this aim: a therapeutic stimulation of the patient´s cognitive function in collaboration 
with a neurotrophic agent, which has to be administered directly into the brain. The overall 
aim is to develop a treatment which could counteract degenerative changes in AD. The focus 
has thus been to elucidate the possibility of implementation of a therapeutic treatment of 
various impaired functions of the patients, symptoms which are committed AD combined 
with gangliosides to stop or slow down the degeneration of neural processes, which are the 
supposed pathological mechanisms of Alzheimer disease. These studies give information of to 
what extent we can rely on these therapeutic strategies in AD treatment. The scientific 
approach is new and focus has been on methodological issues and not the therapeutic results. 
6 .1 Methodological and theoretical considerations 
The studies in the thesis are open studies and the number of participants small, which makes 
the use of statistic methods not possible and could be used only for rCBF. A combination of 
different theoretical approaches and methodologies for evaluation has been done in order to 
strengthen the obtained results.  
The used combination of different methodologies makes it possible to obtain complementary 
findings and to view the interventions from different perspectives and thus gain a deeper 
understanding of the topic/subject being studied (cf. [169, 174, 175]). In that way the 
methodology used may be seen as mixed methods according to methodology and methods in 
an article by Welford et al. [174]. In according to Burke Johnson et al. [176], definitions on 
criteria of demarcation of mixed methods is ongoing. However, these methods used gives also 
possibilities to quantify results and to add clinical observations in the evaluation, to analyse 
how data can change over the examined time. In language examinations by the Aphasia test 
[177, 43], the patients reach the maximum score at the first test occasion, but by adding 
deeper observation, the changes over time could be revealed and provided otherwise hidden 
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knowledge. This in line found with the highlighting the important of extra-test variables 
directed to improve the ecological validity of assessment [178].  
Study I and Study II were quantitative in nature. In such research, validity is often defined as 
the degree to which an instrument measures what it is supposed to measure and reliability as 
the trustworthiness of the instrument used [169].    
All examinations presented in the tables in the original  Paper  I, II, III and V were tested for 
validity and reliability and the instruments used are those commonly used to measure patient’s 
cognitive, physical, and language disabilities; together with clinical various laboratory tests 
and brain imaging.  
The performances of activities were documented at real time, which is the extent to which a 
measure measures what it is supposed to measure. Our Activity scale, which was developed 
for this study to follow and reveal the patient’s level of independence in the performance of a 
task or activity, is, however, not reliability tested. This is a limit but it should also be 
considered that it assesses the cognitive demands required in the patient’s everyday 
environment, that executive functions are hard to assess and is best done in an actual life 
situations [178].   
The CGI form is commonly used in evaluations in dementia trials [179, 180]. In Study IV, the 
CGI form was modified by providing space for voluntary comments. The quotes from the 
spouses’ voluntary comments enable the reader to extend his/her knowledge of how and why 
spouses judged the patient’s preserved skills, behaviours, identity and the content of 
incomprehensive situations. However, another researcher with different pre-understanding 
might have presented other results [181]. The sample size is small, however, and the aim is 
not to uncover general facts but rather to provide a perspective or convey possibilities (cf. 
[182, 169]). Interrater reliability was estimated by means of an independent co-examiner 
[169]. An attempt was made to give rich descriptions of the steps of each process in the 
analysis. Credibility is presented and reported in the analysis, and includes supporting 
quotations taken directly from the data material [182, 169].  
To reduce variation in the study, the underlying data in Paper I-V are based on a rather 
homogenous sample – all the persons are 50-70 years old, living at home. In Paper II, III and 
V, four out of five of the patient group consisted of females, which is consistent with most 
studies on care-giving [183]. In Paper I and IV, 4 out of 5 of the patient were male.  
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Of available nursing theories, which could to be employed as a base in psychiatric-dementia 
research, the Travelbee’s nursing theory was used in Paper III. This theory fits to: the 
procedures in SAT programme; the approach used to reach the individual’s goal; in assisting 
both individual and family; the use of communication as a process; validation the patients; 
and include relationships as an integral part of assessment for care.   
The patients have in this complex study been involved in a continuous dialogue, especially in 
the development and implementation of the SAT-programme. The importance to involve the 
patients in health care has earlier been documented in a thesis by Sätterlund-Larsson [184].  
However, the Roy adaptation model [185] would in Alzheimer’s disease research also be an 
alternative nursing theory, if the goal of nursing would be to promote adaptive responses 
through manipulation of the contextual stimuli [186]. Another approach could be to measure 
the power for self-care as physical, emotional, social and cognitive factors interact to produce 
functional patterns for persons of all ages. Orem’s self-care deficit nursing theory may then be 
an interesting intervention of the power of patients’ self-care actions [187, 188]. That is, may 
be, if low self-care ability can be considered as a reason or a consequence of the type of care 
given by persons in question. Orem’s theory has been a well-established base for measuring 
the power for self-care in several instruments [189]. These two theories do not, however, fit 
the use of the involved approaches and procedures as well as the theory by Travelbee [147]. 
6 .2 Medical considerations 
The ICV administration of ganglioside GM1 into the brain 
In Paper I and Paper II, the IVC infusion with the localization of the catheters bilateral to the 
frontal lateral ventricles was used as a technically favourable neurosurgical solution. In Paper 
I, the Teflon tubing connected to the catheters had a tendency to slide as occurred in Patients 
2 and Patient 3. On the contrary when the tubing was replaced with a one-pieced extension 
catheter, the problem was eliminated. This problem has also be seen in other studies, in which 
a CT brain scan 6 days postoperatively showed that the ventricular catheter had become 
displaced and required re-site operation of the catheter [190].   
Further in Paper I, after the neurosurgeon had contracted the subdural hematoma in two 
patients, the routine at lumbar puncture was changed to less fluid sampled. The tapped fluid 
was replaced with physiological saline and this complication was not met in any patient after 
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changing of the routine. However, the same problems also occurred as in a study with seven 
patients at different clinical centres in the UK. They assessed effect of continuous IVC 
infusion of pentosan polysulphate in human prion disease. One patient had an asymptomatic 
right caudate haematoma which was detected on postoperative imaging. In the study was also 
documented, that complications of intraventricular catheterization were frequent. Catheters 
were placed uni- or biventricular. Catheter-site problems occurred in four patients and early 
complications in two of these four (symptomatic subcortical ischemic stroke and 
postoperative pyrexia) [191].   
Further studies documented in this area is a report of 11 Japanese patients in which subdural 
fluid collection was observed on CT scans in most cases, meaning in 10 of 11 cases [192].    
Lumbar puncture affairs 
In Paper II, one patient refused lumbar puncture (LP), a problem seen of different kind in 
investigations. Other studies have looked into this matter. A study on risk factors at lumbar 
punctures just for develop Post-Dural Puncture Headache (PDPH) have noted as non 
modifiable risk factors: age, female gender, low BMI, history of prior PDPH, and history of 
chronic headache. However, over the age of 60, the PDPH is rare [193]. To determine the 
frequency and risk factors of PDPH in research volunteers in a large series of LPs, no 
instances of epidural hematoma, infection, or radiculopathy were identified, and headaches 
were infrequent (5.6%) [194].   
Medical findings  
New data are was given of reference of therapeutic levels of ganglioside GM1 in lumbar CSF, 
which could be used within AD research or other neurodegenerative diseases. The findings in 
the first study (Paper I) and preliminary study (Paper II) showed that the therapeutic window 
was between 20 and 30 mg/24h. These also showed that therapeutic levels were not reached 
in the previous treatment studies. These used the doses of 100-300 mg of GM1/24h as given 
intravenously, subcutaneously or intramuscularly and are found in large studies of stroke, 
Parkinson’s disease and spinal cord injuries [195]. The therapeutic window is evidently rather 
narrow for intraventricularly administered ganglioside GM1. 
Our studies suggest that the IVC administration of GM1 described here is the method of 
choice for treatment of brain disorders, with substances which are not passing the blood-brain 
barrier. In an attempt to overcome those problems, treatment with intravenous doses of 2 g of 
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GM1 in 3 days a week for 8 weeks of patients with Parkinson’s disease were given. They all 
developed hyperlipidaemia [196].  
The biochemical alterations in CSF showed increased values for HVA and 5- HIAA were 
interpreted as indicative of increased biosynthesis and turnover of dopamine and serotonin. 
Thus the effect of GM1 on the level of HVA indicates an effect on the dopaminergic function 
in the brain by GM1. It is in agreement with dopaminergic neurons restoration of function 
after mechanical or biochemical lessons [195] and beneficial of GM1 effect in Parkinson’s 
disease [197].  
In Paper I and Paper II the somatostatin level increased in all patients, which is interesting as 
the level is reported low in dementia [198]. An increase of somatostatin has also been shown 
as a result of a caring treatment concomitant with functional improvement [199]. The 
increased CSF levels of somatostatin thus suggest a relation to improvement in brain function. 
The somatostatin level has been shown to be related to cognitive function [200].  
Cerebral blood flow was slightly increased in 4 of the 5 patients in Paper II, however, not 
significant. Untreated AD patients show a continuous diminution of the rCBF with time 
[201]. The results are a further indication of possible positive influence on the brain in our 
study and suggest that the degenerative process had not accelerated during the treatment year. 
The mechanism of action of GM1 
It is not known how GM1 acts in the brain. It is suggested that treatment with GM1 would 
lead to insertion also of those GM1 molecules in the neuronal membrane. The new GM1 
molecules would bind Ca 2+ as counter-ion and increase the inflow of Ca2+ during synaptic 
transmission (efficient communication between these cells is crucial to the normal 
functioning) and the release of transmitter.  Our research team had observed the strong 
binding of CA2+ to gangliosides which several studies had confirmed [202], and also that that 
the apparent association constant depends on the surrounding ionic strength.  
In our research team already in1980 [203] suggested that Ca2+ - associated gangliosides on the 
outer surface of the presynaptic membranes might be replaced by NA+ as counter-ion by the 
action potential (presynaptic is the part of the cell membrane of an axon terminal that faces 
the cell membrane of the neuron with which the axon terminal establishes a synapse). This 
would facilitate transformation of the membrane lipid bilayer into a micellar state (a micelle is 
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an aggregate of surfactant molecules dispersed in a liquid colloid) necessary for the fusion of 
the synaptic vesicle and the plasma membrane, and release of transmitter. The Ca2+, replaced 
by Na+ as counter-ion to gangliosides, would participate in the influx of Ca2+ into the synapse. 
Beta amyloidad related lesions begin with degeneration of ACh neurone, followed by 
accumulation of intra neuronal β amyloid (Aβ), NFTs , synaptic loss and neuronal death 
[204]. Ganglioside has later been shown to be involved in the formation of plaques by a 
combination to Aβ [205]. It is not known how a treatment with very high doses of GM1 will 
influence Aβ. Our findings suggest that there is no acceleration of the disease with such 
treatment and it is possible that the high concentration of GM1 in the brain protect from the 
negative effect of Aβ as suggested by Kreutz 2011 [206].  
6 .3  Therapeutic treatment considerations 
Stimulation influence from milieu or drug treatment      
The increase of cerebrospinal fluid levels of monoamine metabolites, neuropeptides and 
somatostatin in CSF was only seen in connection with the GM1 treatment in Paper II. 
However, monoamine changes in environmental stimulation of demented persons have earlier 
been investigated previously [207]. In this study activation was performed in two different 
long-stay ward hospitals with patients who had a moderate degree of dementia. The 
evaluation included somatostatin concentrations and monoamine metabolites, which were 
analysed before and after a programme with intensified intellectual, emotional, emotional and 
environmental stimulation of one group (n=11) during a two month period. The control group 
(n=13) had no such environment. Some of the psychological parameters were changed during 
the study period indicating slight improvement in the activated group and further deterioration 
in the control group. Although the number of included patients was low, the CSF 
concentration of somatostatin increased significantly in the activated group during the 
treatment period and decreased in the control group. It was concluded that the increase in the 
CSF somatostatin concentration might be a response to the increased environmental 
stimulation [207]. The next article of this, reported that the HVA (homovanillic acid) 
concentrations increased in CSF in the treatment group and decreased in the control grope, no 
change was evident in 5-HIAA or HMPG concentrations in either group. It was suggested that 
environmental factors can influence biochemical markers of transmitter activity [208].  
Another study, with similar design, found that somatostatin in CSF increased by promoting 
care, concomitant with functional improvement [199].  
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Findings related to therapeutic treatment 
Paper I. In the first study (Paper I), the spouses lost much of their energy before the end of 
the treatment year. That result may be taken in consideration that the patients really asked for 
more training and activation of the research assistant. However, there are similar experience 
from other studies of caregiver’s taken care of patients with AD for a longer periods [209], 
some of these put an importance to including personality of the caregivers of the caregiving 
process [210]. In this study some respite from homecare through training by professionals 
outside the home is suggested as long as the patients have mild to moderate AD.   
In Paper III (the SAT programme), activities and tasks hard to solve by the patients 
themselves was successful trained with use of visuosospatial-sterognostic sense strategies to 
help the patients to overcome great restriction of performance. In another study the use of 
plenty of memory support was used which was less successful [211].   
The strategy to ask each patient to look for feature explicit just for the individual patient to 
use as a help to find the way to and from the shop, was successful. All patients learn 
independent to do shopping for lunch. To be lost in the sense of space can evoke feelings of 
insecurity, which might affect the quality of life for the patient. It is therefore emphasized to 
include in the education to the caregiver the importance of this kind of supporting from 
environment, in order to promote the sense of safety and function in daily activities.  
Positive experiences of listen to or following audio-taped instructions have earlier been 
confirmed in Setterlind’s thesis regarding progressive muscular relaxation [212] but not 
hitherto found in dementia studies. This finding in our study, revealed a hidden need of 
relaxation to be considered as it is based on the patients’ own request, within the free choice 
of activities.   
We also found that the implementation of a therapeutic treatment of various impaired 
functions of the patients, demand comprehensive stimulation, activation and training of all 
involved in cognitive, social and physical daily life. The theoretical base for this is that each 
mental function has a specific localisation in the brain, and that there is a need of various 
strategies to activate these parts of the brain. This therapeutic treatment is important to 
stimulate impaired brain areas or other to increase function in preserved parts. 
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The findings in Paper III and Paper V suggest a computer system as an important tool in mild  
rapeutic treatment, to be used to activate and train the patients’ attention, 
concentration, decision taken, simultaneous capacity and memory. Further, the huge amounts 
of words in the computer exercise program stimulate the patients to use their preserved 
language abilities.  
Paper IV. Caring is a process and concerns relationships between people. All the spouses 
arrange social activities and they also paid attention to their partner’s need of support in 
unfamiliar settings. This gave a glimpse of how they viewed their responsibility. Social ties, 
as has been suggested earlier, diminish the effects of daily negative events [213]. The quality 
of the relationship between partner and caregiver is important in dementia care giving [214].  
All the spouses clearly paid attention to the level of activity and the initiatives taken by the 
patients themselves. This is contrary to the opinion of professionals, which is contrary to the 
common opinion, also of professionals. In clinical diagnosis of AD and in studies of 
motivation it is in terms of the loss of theses abilities [215, 216].   
All spouses talked about memory as the only impaired cognitive function. This opinion might 
have been influenced by the fact that impaired memory function is a characteristic symptom 
of AD and subjective memory complaints are often found in the population of elderly adults 
[217].    
Paper V. The NGA, generally used by speech pathologists [218] is suitable in this study, as it 
deals with the complexity of linguistic problems common in patients diagnosed with AD. 
There is no such test or scale available based on or for patients with AD. NGA is intended to 
assess impairment; a ceiling effect may occur and did occur in this study. When a patient 
reaches a maximum score, analysis of their performance is needed to established possible 
changes. The speech pathologist detailed examination of each patient’s performance made 
this possible and she gave thereby also a 1-year overview.  
To take part in everyday talk during one year, like a natural habit was found be well accepted 
as sometimes they use their pocket almanac to tell what had happen. It is important training as 
people with languae disorders are significantly disempowered  in a culture where oral 
language skills are highly ranked [219].  
to moderate AD the
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A collaborative interchange communication and use of topics with relevance and meaning to 
the patients in combination with structure, equal power in discourse, is recommended for this 
patient group as a way to reduce the patients’ pragmatic problem.  
Difficulty in solving mathematical problems was apparent in both oral and written arithmetic 
tasks for four of the five patients. This is known to be present early in AD [220]. That one 
patient had low scores on writing at the start and still lower scores after one year is not 
surprising, as writing disorder is suggested to be an early manifestation of AD [221].  
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7   CONCLUSION 
This thesis evaluates how a treatment program can be made and used in patients with early 
onset Alzheimer´s disease of a mild/moderate degree. The addition of a specific stimulation to 
pharmacologic treatment in dementia adds new knowledge and is a model for test of other 
substances in Alzheimer´s disease. 
The findings in the SAT programme indicate that the complex symptoms in mild to moderate 
AD need multimodal interventions to utilize all remaining abilities and to cover the patients’ 
capacity of performance of common daily tasks. To improve stabile functional outcomes of 
the systematic training, the SAT may be continued during 12-months, at least nine months.  
The initial finding in Paper II, III, and V support the use of stimulation techniques, 
visuospatial strategies with utilizing the senses and a nursing process in which the nurse 
confirms and validates another person. With active participating of the participants in 
systematic training of cognitive, social, and physical activities and a complex tool as a 
personal computer system in conjunction with other interventions in everyday activities may 
help patients to maintain their capabilities and may also offer possibilities of improving. The 
thesis present novel approaches of procedure in treatment of language dysfunction and in 
muscular relaxation. These offer possibilities of improving in the linguistic competence and to 
reduce patients’ basic tension and body awareness.  
The results of the spouses’ comments of their everyday life at home with a partner with AD 
suggest educational intervention concerning: how to understand and manage healthy emotions 
created in the life with a patient with AD, and education how to support and manage visually 
complex symptoms of AD. A respite from homecare through training by professionals outside 
the home should be considered in planning to ease the strain involved in maintaining the 
partner’s capacity to perform daily tasks of patients with mild to moderate AD.  
This is the first attempt to combine a neurotrophic factor, GM1, and specific therapeutic 
treatment stimulation programme to activate the brain in early onset Alzheimer’s disease 
(AD). This study involves treatment with a neurotrophic substance administered directly into 
the brain, hitherto not studied in Alzheimer´s disease, and reinforced with stimulation with an 
individualized activation programme. It was obvious that no patient found the surgery 
troublesome and no patient or relative has expressed regret about participating in the study. 
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This knowledge is important not only for this neurotrophic agent but that assist of the SAT 
programme can be used for various substances aimed at treatment of neurodegenerative 
disorders. 
Although this is a small and open study, according to a variety of measures there might be a 
deviation/difference from the general pattern of decline. However, the 5 patients in study II-V 
did not show deterioration to the extent that can be expected in patients with AD during a 1-
year period [222], according to the results of the comprehensive battery of neuropsychological 
tests showing both increased and decreased scores. The study displays the importance to listen 
carefully to the opinions of the patients and the relatives both with regard to the training 
program and the participating in such a long and complex study.
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8 FUTURE PERSPECTIVES
It is evident that stimulation, activation and training patients with AD results in positive 
effects. However, this treatment needs further evaluation to evaluate both degree of 
improvement and how this is reflected in biologic effects.  
The patients suffered from AD, where a brain damage is evident. This will still be there even 
if the ongoing degenerative process can be stopped. Therefore therapies of AD will be needed 
to, if possible, improve brain function to the highest possible level, and possibly to overcome 
the damage. Practical use of the finding in the SAT programme to utilize the senses to 
successful compensatory other impairment are presented.  Also psychophysical studies have 
shown that performance on perceptual tasks can be improved with training and that 
improvement in perceptual judgments occurs with practice or training, is evident [226].   
The adult CNS retains significant capabilities for structural remodelling and functional 
adaption. These phenomena depend on the capability of the neurons to modify their functional 
properties and their connections, which nowadays is defined as plasticity. That environmental 
stimulation promotes neuronal plasticity in animals has been known since 40 years [227, 228], 
and is also  found in aged animals [229]. There have also come evidence for neuronal 
plasticity in humans when exposure to an enriched environment [230]. Stimuli coming from 
the external world have shown to exert a powerful dual influence on plastic processes in both 
physiological plasticity and injury-induced compensatory processes have been concluded this 
year [231]. Thus, the SAT programme, performed as in this thesis, can be a tool to induce 
positive effects on the nerve cells, counteracting degenerative changes of AD.  
It is rationale to consider a program as SAT as a base for treatment of AD. However, in earlier 
studies much more attention has been focused on pharmacologic treatment. The addition of a 
specific stimulation in a therapeutic treatment to pharmacologic treatment in dementia adds 
new knowledge, and is a model for test of other substances in AD. Full effect of a 
pharmacologic treatment in AD should therefore also include the aspect of stimulation of the 
brain, to evaluate all possible effects of the drug.    
The influence on the dopaminergic function and reported beneficial effect in Parkinson’s 
disease (PD) of GM1 treatment, suggest that the presented treatment method will be 
particularly useful for patients with Parkinson’s disease. This has already been tested and 
results of a five year open study has been published in year 2010 suggesting that long-term 
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GM1 use by PD patients is safe and results in benefit [223]. Future research with GM1 may 
be in direction of research of increasing the release of brain-derived neurotrophic factors, 
which has been reported 2011 [224]. Another possibility may be a protective role for GM1 in 
betaamyloid-induced toxicity [225].  
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